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(ESCC). One of the major risk factors for the development of EAC is Barrett's esophagus (BE). BE is defined
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stratified squamous epithelium of the esophagus. Currently, the cell of origin for human BE has yet to
identified. Using an innovative 3D organotypic culture system, we explored the role of inhibition of Notch
signaling promotion of transdifferentiation of esophageal epithelial cells to BE. Our RNA microarray and
tissue microarray (TMA) data support the premise that loss of Notch signaling is involved in BE. Inhibition of
Notch signaling by dominant-negative-Mastermind-like (dnMAML), in concert with MYC and CDX1
overexpression, promoted transdifferentiation of esophageal epithelial cells towards BE as demonstrated by
increased expression of columnar keratins and glandular mucins with decreased expression of squamous
keratins. Our data show KLF4 and HATH1, as downstream effectors of the inhibition of Notch signaling, are
involved in the initiation of BE. We investigated whether these findings translated into a genetically
engineered mouse model. We addressed this by engineering transgenic mice to conditionally overexpress
MYC specifically in the esophageal epithelium with the EBV-L2 (L2) promoter. We used a Tet-ON system to
conditionally express MYC. To achieve this we created two new transgenic mice: TetOp-Myc and
L2-rtTA;TetOp-CreERT2. We bred L2-rTta; TetOp-Myc mice with K14-Cdx2 and TetOp-dnMAML mice, in
order to replicate our in vivo studies. These studies are ongoing. Invasion is a theme common to BE/EAC and
ESCC. As a separate consideration, we investigated the mechanisms underlying invasion in ESCC. Using
esophageal epithelial cells transformed by overexpression of EGFR and p53R175H, we found a novel link
between p53R175H and c-Met, a receptor tyrosine kinase. These transformed cells show increased expression
of the c-Met receptor mediated by p53R175H overexpression. We show inhibition of c-Met expression in the
transformed cells (EPC-hTERT-EGFR-p53R175H) diminishes invasion. Our data suggest a new avenue of
therapeutics for ESCC through the use of c-Met inhibitors.
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ABSTRACT 
IDENTIFICATION OF MOLECULAR MECHANISMS UNDERLYING THE 
DEVELOPMENT OF BARRETT’S ESOPHAGUS  
Maria Eugenia Vega 
Anil K. Rustgi 
 Esophageal cancer is one of the deadliest cancers in the U.S and worldwide.  
Esophageal cancer is characterized by two subtypes: esophageal adenocarcinoma 
(EAC) and esophageal squamous cell carcinoma (ESCC).  One of the major risk factors 
for the development of EAC is Barrett’s esophagus (BE).  BE is defined as incomplete 
intestinal metaplasia characterized by the presence of columnar and goblet cells in the 
formerly stratified squamous epithelium of the esophagus.  Currently, the cell of origin for 
human BE has yet to identified.   
Using an innovative 3D organotypic culture system, we explored the role of 
inhibition of Notch signaling promotion of transdifferentiation of esophageal epithelial 
cells to BE.  Our RNA microarray and tissue microarray (TMA) data support the premise 
that loss of Notch signaling is involved in BE.  Inhibition of Notch signaling by dominant-
negative-Mastermind-like (dnMAML), in concert with MYC and CDX1 overexpression, 
promoted transdifferentiation of esophageal epithelial cells towards BE as demonstrated 
by increased expression of columnar keratins and glandular mucins with decreased 
expression of squamous keratins.  Our data show KLF4 and HATH1, as downstream 
effectors of the inhibition of Notch signaling, are involved in the initiation of BE.   
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We investigated whether these findings translated into a genetically engineered 
mouse model.  We addressed this by engineering transgenic mice to conditionally 
overexpress MYC specifically in the esophageal epithelium with the EBV-L2 (L2) 
promoter.  We used a Tet-ON system to conditionally express MYC.  To achieve this we 
created two new transgenic mice: TetOp-Myc and L2-rtTA;TetOp-CreERT2.  We bred L2-
rTta; TetOp-Myc mice with K14-Cdx2 and TetOp-dnMAML mice, in order to replicate our 
in vivo studies.  These studies are ongoing.   
Invasion is a theme common to BE/EAC and ESCC.  As a separate 
consideration, we investigated the mechanisms underlying invasion in ESCC.  Using 
esophageal epithelial cells transformed by overexpression of EGFR and p53R175H, we 
found a novel link between p53R175H and c-Met, a receptor tyrosine kinase.  These 
transformed cells show increased expression of the c-Met receptor mediated by p53R175H 
overexpression.  We show inhibition of c-Met expression in the transformed cells (EPC-
hTERT-EGFR-p53R175H) diminishes invasion.  Our data suggest a new avenue of 
therapeutics for ESCC through the use of c-Met inhibitors.          
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Background and Significance  
Barrett’s esophagus (BE) is characterized by the switch of the normal squamous 
epithelium to a small intestinal-type epithelium (Shaheen and Richter 2009).  
Gastroesophageal reflux disease (GERD) is one of the most common risk factors for BE 
development.  Both GERD and BE are major risk factors for esophageal 
adenocarcinoma (EAC) (Lagergren, Bergstrom et al. 1999; Gibson, Dhaliwal et al. 
2013).  Esophageal cancer can be classified into one of two major subtypes: esophageal 
squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC).  In the 
United States there has been an increase in the cases of EAC by 600% since 1975 
(Pohl and Welch 2005).  The rise in cases of EAC is due to the increase in the 
prevalence of BE (de Jonge, van Blankenstein et al. 2014).  Esophageal cancer is one of 
the deadliest cancers in the US, with a 5-year survival rate of 17.3% in 2013 (Howlader, 
Noone et al. 2013). 
There are other risk factors associated with the development of BE, apart from 
GERD, including the following: obesity, cigarette-smoking and eradication of H.pylori 
infection (Badreddine and Wang 2010).  The progression from BE to EAC occurs via a 
multistep process in which the metaplastic epithelium evolves to low-grade dysplasia, 
high-grade dysplasia and culminating in EAC.  Some of the genetic alterations known to 
occur in BE are overexpression of cyclin D1 and EGFR oncogenes and loss of p53 and 
p16 tumor suppressor genes (Graham and McDonald 2010).  Yet, the cell that gives rise 
to BE is still unknown.  Therefore, the elucidation of the cell of origin for BE can provide 
not only an understanding of the mechanisms underlying metaplastic development, but 
also give insights into genetic factors that can drive progression to EAC.     
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The squamous esophageal epithelium  
The esophageal epithelium functions to protect the underlying tissue from any 
external damage, such as that from microorganisms or toxic materials (Squier and 
Kremer, 2001).  The esophageal epithelium is a stratified squamous type of epithelium, 
as opposed to the stomach and small intestine which consist of a simple epithelium.  
The esophageal epithelium can be characterized further into three distinct cellular layers: 
basal, suprabasal and superficial squamous (Figure 1).  The esophageal basal cells are 
cuboidal in shape with a high nuclear to cytoplasmic ratio.  Basal cells proliferate and 
give rise to differentiated suprabasal cells.  There are various factors known to stimulate 
proliferation of the esophageal basal cells, including epidermal growth factor (EGF), 
transforming growth factor-α (TGF-α), platelet-derived growth factor (PDGF) and 
interleukin 1 (IL-1) (Feliciani, Gupta et al 1996; Squier and Kremer 2001).  The rate of 
proliferation can also be modulated by other factors, such as diurnal variation, stress and 
inflammation.  It has been shown that subepithelial inflammation can stimulate mitosis in 
basal cells.  By contrast, severe inflammation can reduce proliferation (Kamer, Krebs et 
al. 1999; Squier and Kremer 2001).   
The basal compartment is where putative stem/progenitor cells may reside.  The 
identification and characterization of stem cells responsible for the maintenance of the 
esophageal epithelium remains elusive.  Slow-cycling cells have been experimentally 
designated as label-retaining cells (LRCs).  In the esophagus a small subset of epithelial 
cells can retain 3H-thymidine or BrdU for several months (Croagh, Phillips et al. 2007).  
Our group has used Hoechst dye exclusion to identify a subpopulation of esophageal 
epithelial cells, experimentally referred to as the side-population (SP), which have the 
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ability to self-renew and differentiate when grown in 3D organotypic cultures and in 
mouse injury models (Kalabis, Oyama et al. 2008).   
Transgenic label-retaining cell assay has shown the presence of a single 
progenitor cell population in the basal layer of the mouse esophagus, which can 
contribute to tissue homeostasis and participate in the repair of the esophageal 
epithelium upon injury (Doupe, Alcolea et al. 2012).  Similar studies, using transgenic 
lineage labeling assays, show loss of Notch signaling in the progenitor cells which leads 
to loss of differentiation of these progenitor cells (Alcolea, Greulich et al. 2014).  
Recently, Sox2 has been identified as a potential marker of putative stem/progenitor 
cells in the esophagus basal cells (Liu, Jiang et al. 2013).  Moreover, whole mount 
staining of the human esophageal epithelium reveals that quiescent cells expressing 
putative stem cell markers (CD34+EpCAM-) reside in the tips of the esophageal papillae 
(Barbera, diPietro et al. 2014).  Interestingly, single cell isolation using the stem cell 
markers CD34 and EpCAM show no significant differences in self-renewal in 2D cultures 
or differentiation in 3D cultures (Barbera, diPietro et al. 2014).  
The differentiation of the esophageal epithelium can be mediated by the 
presence of various factors, such as extracellular calcium, phorbol esters, retinoic acid 
and vitamin D3 (Dotto 1999; Dotto 2008).  As basal cells enter the differentiation phase, 
suprabasal cells become larger, begin to flatten and also start to accumulate keratins, 
which are cytoplasmic intermediate filaments (Figure 1).  The proliferative basal 
esophageal epithelial cells express keratin 5 and keratin 14, and differentiated 
suprabasal cells express keratin 4 and keratin 13.  Finally, in the terminal differentiation 
stage, the superficial squamous cells express involucrin, profilaggrin and desmocollins 
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(Squier and Kremer 2001).  These cells desquamate into the lumen, and the process of 
epithelial renewal occurs continuously.     
Regulation of the esophageal epithelium by developmental pathways 
The development and differentiation of the esophageal epithelium are mediated 
through various signaling pathways, such as WNT, Hedgehog and Notch.  During 
development both the esophagus and trachea arise from a same foregut tube.  The 
separation of the foregut tube to form the esophagus (dorsal) and trachea (ventral) is 
mediated by certain signaling pathways.  One of the pathways shown to be critical in this 
process is the WNT (Wingless) signaling pathway.  The importance of WNT signaling 
during esophageal development has been established through certain mouse studies. 
For example, removal of Wnt2 and Wnt2b in mice leads to a loss of the separation of the 
esophagus and trachea (Goss, Tian et al. 2009).  Furthermore, deletion of β-catenin, a 
downstream mediator of WNT signaling, during development leads to esophageal 
atresia and the formation of a tracheoesophageal fistula (Jacobs and Que 2013).   
Hedgehog signaling has been shown to be critical during the development of the 
esophagus.  Sonic Hedgehog (SHH) is expressed throughout the esophagus during 
development and later it is restricted to the distal esophagus (Ramalho-Santos, Melton 
et al 2000).  Study of Shh-/- mice show a defect in the separation of the esophagus and 
trachea during development (Litingtung, Lei et al 1998; van den Brink 2007).  
Furthermore, knockout of specific SHH effector genes, Gli2 and Gli3 (Gli2-/-; Gli3-/-) 
results in complete atresia of the esophagus (Motoyama, Liu et al. 1998; van den Brink 
2007).    
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The transcription factors Sox2 and Nkx2.1 have been shown to be critical in the 
separation of the anterior foregut into the trachea and esophagus.  Nkx2.1 is normally 
expressed in the lung, thyroid and brain.  Nkx2.1 expression in the foregut is restricted to 
the developing trachea.  Studies with Nkx2.1-/- mice show inhibition the separation of 
the anterior foregut, leading to the formation of one common lumen connecting the 
pharynx to the stomach (Minoo, Su et al 1999; Que, Okubo et al. 2007).  Furthermore, 
studies with conditional deletion of Sox2 in mice show defective separation of the 
foregut, and the mutant esophagus show increased levels of Nkx2.1 upon loss of Sox2. 
(Que, Okubo et al. 2007).  Morphological analysis of the Nkx2.1-/- mutant esophagi has 
shown increased levels of Sox2 (Jacobs and Que 2013).   
Notch signaling is active in the basal layer of the esophagus.  Jag1, Jag2, Notch1 
and Notch2 are highly expressed in the basal layer of the mouse esophagus and this 
expression decreases in the suprabasal layer (Sander and Powell 2004).  Furthermore, 
Notch1 activation is observed in the onset of the stratification of the esophageal 
squamous epithelium.  Inhibition of Notch signaling in the normal esophageal epithelium 
causes a loss of the normal differentiation of the epithelium, observed by loss of 
involucrin expression.  This process has been shown to be mediated by Notch1 and 
Notch3 regulation of early differentiation genes (Ohashi, Natsuizaka et al 2010).  
Metaplasia  
Metaplasia is defined as the switch of one cell type with another cell type.  The 
development of this new cell type is usually an adaptive response to some external or 
environmental insult.  Metaplasia is known to occur in various tissues such as the lung, 
cervix, stomach and esophagus.  For example, in lung, the injury caused by cigarette-
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smoking promotes the replacement of the mucus-secreting ciliated pseudostratified 
columnar epithelium of the normal lung with a stratified squamous epithelium, referred to 
as squamous metaplasia.  In the esophagus injury from GERD and cigarette-smoking 
lead to the replacement of the normal esophageal squamous epithelium with columnar 
cells or enterocytes and mucin-producing cells, reminiscent of the small intestinal 
epithelium, except for the lack of Paneth cells and enteroendocrine cells (Figure 2).  This 
is referred to as intestinal metaplasia.  Intestinal metaplasia occurs in the stomach as 
well.  Gastric intestinal metaplasia is characterized by the appearance of an intestinal 
epithelium in the stomach, including the presence of enterocytes, goblet cells and 
Paneth cells (Correa, Piazuelo et al. 2010).  In most cases metaplasia may be a 
desirable event.  Yet, it is important to note that in same contexts, metaplasia can evolve 
to dysplasia and cancer, representing an undesirable event.   
Cell of origin for Barrett’s esophagus 
 There are several hypotheses for the cell of origin for BE, and these include: (1) 
transdifferentiation of cells from the esophageal basal layer or from the ducts of the 
esophageal submucosal glands, (2) migration of cells from the esophago-gastric junction 
(EGJ) or gastric cardia and (3) bone marrow derived progenitor cells.   
 Transdifferentiation is defined as a process by which one somatic cell change 
into another somatic cell, without undergoing a preceding pluripotent or progenitor stage 
(Orkin and Zon 2008).  Potential evidence for transdifferentiation of the normal 
squamous epithelium to BE has been demonstrated in certain studies (Figure 2A).  
Studies of human BE biopsies using laser capture microdissection followed by DNA 
sequencing showed the same p16 mutation found in both the squamous epithelium and 
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BE, suggesting a common cell of origin (Leedham, Preston et al 2008).  Moreover, in 
vitro studies using human immortalized esophageal epithelial cells overexpressing MYC 
and CDX1 showed a partial transdifferentiation to BE with expression of columnar 
keratins K8 and K19 as well as MUC5AC (Stairs, Nakagawa et al 2008).  Furthermore, a 
study of human BE biopsies has shown that esophageal squamous epithelial cells 
express intestinal genes, namely CDX2 and MUC5AC, but have yet to acquire a 
columnar or goblet cell morphology (Hahn, Blount et al 2009).  Overall, these studies 
provide potential evidence to support the plasticity of the esophageal squamous basal 
cells to transdifferentiate into the BE epithelium. 
 The second supposition for the potential cell of origin of Barrett’s esophagus 
suggests the existence of residual embryonic cells at the EGJ or gastric cardia (Figure 
2B).  P63 global knockout mice show the expansion of residual embryonic cells upon the 
loss of the squamous epithelium.  These residual embryonic cells replace the squamous 
epithelium with a columnar lined esophagus (Wang, Ouyang et al 2011).  In addition, 
studies of the L2-Interleukin (IL)-1β transgenic mouse showed the development of 
esophagitis, BE and EAC (see later section).  Lineage labeling of putative gastric cardia 
stem cells by Lgr5-GFP showed presence of gastric cardia derived cells in the BE 
lesions (Quante, Bhagat et al. 2012).  Furthermore, recent studies comparing human BE 
to the gastric cardia epithelium have shown a similar proliferative and gene expression 
pattern between BE and the gastric cardia (Lavely, Nicholson et al. 2014).   
 Thirdly, it has been proposed that the cell of origin for BE may derive from the 
bone marrow (Figure 2C).  Studies with rodents that undergo a surgical 
esophagojejunostomy, reveals the emergence of severe erosive esophagitis and BE.  
Female rats were lethally irradiated after which their bone marrow was reconstituted with 
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bone marrow of male rats.  Following bone marrow transplantation the rats underwent 
esophagojejunostomy.  Analysis of the BE lesions by FISH for the Y chromosome (male 
derived) showed the presence of male bone marrow derived cells (Sarosi, Brown et al 
2008).   
Genetic alterations in Barrett’s esophagus  
 The study of BE has been limited mostly to the analysis of human BE biopsies.  
Yet, the histopathological analysis of these biopsies has led to the discovery of key 
genetic alterations that occur in BE metaplasia (Figure 3).  One such genetic change is 
the expression of the homeobox transcription factors CDX1 and CDX2, which are 
expressed in BE.  CDX1 and CDX2 are part of the caudal homeobox family of 
transcription factors, which are important for the development and differentiation of the 
small intestine and colon (Guo, Suh et al 2004).  CDX2 has been found to be expressed 
in early esophagitis prior to the detection of BE, suggesting its expression may be an 
early event in the development of BE (Eda, Osawa et al 2003).  Interestingly, conditional 
Cdx2 knockout in the small intestine of the mouse results in squamous metaplasia (Gao, 
White et al. 2009).  Moreover, ectopic expression of CDX2 specifically in the mouse 
esophagus (K14-Cdx2) showed reduced basal cell proliferation and altered cell 
morphology, indicative of early initiation of BE (Kong, Crissey et al. 2011).   
 Another gene that has been linked to BE is bone morphogenetic protein 4 
(BMP4).  BMP4 belongs to the transforming growth factor β (TGF-β) family, which is 
involved in controlling cellular differentiation, migration and proliferation.  Studies of BE 
biopsies have found BMP4 and its downstream targets, phospho-SMAD 1/5/8 and ID2, 
are expressed in BE, but absent in the normal adjacent squamous epithelium (Milano, 
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van Baal et al 2007).  Furthermore, studies of severe reflux esophagitis in rats showed 
activation of the BMP pathway in the inflamed squamous epithelium and in BE (Sarosi, 
Brown et al 2008).   
 Genetic alterations involving the silencing of tumor suppressor genes have been 
found to be present in BE metaplasia.  One example is the loss of the CDKN2A/p16INK4A 
(p16) tumor suppressor gene.  CDKN2A/p16INK4A is lost in 85% of BE samples (Wong, 
Paulson et al. 2001; Maley 2006).  In the case of the CDKN2A/p16INK4A locus most 
patients have either loss of heterozygocity (LOH) or methylation of the promoter.  In BE 
patients LOH of the tumor suppressor TP53 has also been described, but importantly 
this event is rarely seen in the absence of LOH of p16 (Maley, Galipeau et al. 2004).  
This suggests TP53 LOH is a secondary event in the development of BE metaplasia.  
Aside from TP53 LOH, mutation of p53 has been reported as a prognostic marker for 
progression from BE to EAC (Sikkema, Kerkhof et al. 2009).    
 Genetic alterations in esophageal adenocarcinoma (EAC)  
BE and gastroesophageal reflux disease (GERD) are the major risk factors for 
EAC.  Another risk factor for EAC is obesity.  Specifically, studies have shown a positive 
association between body mass index (BMI) and the risk of EAC (Kubo and Corley 
2006).  Alcohol and tobacco have been found to be associated only moderately with 
EAC risk (Freedman, Abnet et al 2007).  Lastly, Helicobater pylori (H.pylori) infection, 
which in the distal stomach may act as a carcinogen, has been shown to have an 
inverse relationship with EAC.  Therefore, H.pylori may be protective for the 
development EAC (Rokkas, Pistiolas et al 2007).   
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During the progression from BE to EAC, cells may accumulate a number of 
genetic alterations that confer a growth advantage (Figure 3).  For example, in EAC the 
oncogenes cyclin D1, E, B1 and A are known to be activated (Arber, Lightdale et al 
1996; Geddert, Heep et al. 2005; Zhang, Spechler et al. 2009).  EAC also shows 
increased expression of transforming growth factor (TGF-α), epidermal growth factor 
(EGF) and EGFR receptor (EGFR) (Brien, Odze et al 2000; Brito, Filipe et al. 1995; 
Zhang, Spechler et al. 2009).  Key tumor suppressor genes implicated in EAC include 
p16, p53, p14ARF, p27 and adenomatous polyposis coli (APC).  In EAC, silencing of the 
p16 promoter has been reported in 45-54% of cases (Wong, Barrett et al. 1997; Zhang, 
Spechler et al. 2009).  Furthermore, in EAC, TP53 LOH has been reported to be present 
in 50-90% of cases (Hamelin, Flejou et al. 1994; Zhang, Spechler et al. 2009).  Similarly, 
75-83% of EAC have no detectable p14ARF or p27 (Huang, Peters et al. 2009; Singh, 
Lipman et al. 1998; Zhang, Spechler et al. 2009).  Lastly, methylation of APC has been 
found in 80% of BE patients with high-grade dysplasia or EAC (Kawakami, Brabender et 
al. 2000; Zhang, Spechler et al. 2009).  Furthermore, during the progression of dysplasia 
in BE there is a decrease in membranous E-cadherin and β-catenin and an increase in 
nuclear localization of β-catenin (Bailey, Biddlestone et al. 1998; Washington, Chiappori 
et al. 1998; Zhang, Spechler et al. 2009).   
 Recently, studies of whole-genome sequencing of EAC have revealed 
chromosomal amplification at 18q11.2 in 21% of EAC, where the gene GATA6 resides.  
Further analysis reveals GATA6 amplification correlates with poor survival in EAC 
patients (Lin, Bass et al. 2012).  A whole-exome sequencing study of EAC has identified 
26 significantly mutated genes (Dulak, Stojanov et al. 2013).  Novel mutations in ELMO1 
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and DOCK1, which are upstream modulators of the RAC1 GTPase, suggest the possible 
activation of the RAC1 signaling pathway in EAC (Dulak, Stojanov et al. 2013).   
Epidemiology and genetic alterations of esophageal squamous cell 
carcinoma (ESCC) 
 Esophageal cancer can exist in two different forms: esophageal adenocarcinoma 
(EAC) and esophageal squamous cell cancer (ESCC).  ESCC is mainly observed in 
African-American and Asian populations, while EAC mainly affects the white 
(Caucasian) population.  Therefore, it is not surprising that the environmental risk factors 
for ESCC may differ from those for EAC (Figure 3).  ESCC has linked to tobacco use, 
alcohol consumption, ingestion of salt-cured, salt-pickled and moldy foods, and the 
consumption of hot beverages (Zhang 2013).  Some of the genetic changes found in 
ESCC include the following: EGFR and cyclin D1 amplification, as well as inactivation of 
p16INK4A, p53 and p120-catenin tumor suppressor genes.  
 The epidermal growth factor receptor (EGFR) is part of the ErbB growth factor 
tyrosine kinase receptor family, which activates genes that can promote cell cycle 
progression, angiogenesis, survival, migration and invasion (Sibilia, Kroismayr et al. 
2007).  Overexpression of EGFR has been reported in 60-70% of ESCC tumors 
(Hanawa, Suzuki et al. 2006).  Cyclin D1 amplification or overexpression leads to the 
constitutive activation of the cyclin D1/CDK4/6 pathway.  Cyclin D1 amplification is found 
in 30-75% in cases of ESCC (Nakagawa, Zukerberg et al. 1995; Zhang 2013).  
Furthermore, increased CyclinD1 expression is correlated with poor prognosis (Hirai, 
Kuwahara et al. 1999; Zhang 2014).   
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Another critical genetic alteration in ESCC is the inactivation of the tumor 
suppressor p16INK4A.  In studies of primary ESCC 14 of 27 cases have point mutations or 
microdeletions of the p16 coding gene (Mori, Miura et al. 1994; Zhang 2013).  Lastly, 
during the development of ESCC there are mutations of the tumor suppressor gene p53 
(McCabe and Dlamini 2005).  These mutations lead to impaired downstream function of 
the p53 tumor suppressor.  Some of the most common of these mutations that occur in 
ESCC are the R175H, R248W and R273H (McCabe and Dlamini 2005).  These 
mutations fall within the DNA binding domain of p53.  Mutations in this region cause p53 
to lose its specificity to DNA sequences either by causing global conformation changes 
or by interfering with promoter-specific contact (Joerger and Fersht 2007).       
Recent genome-wide studies have investigated ESCC cases using whole-exome 
sequencing in order to identify significantly mutated genes (Song, Li et al.2014).  Six 
tumor associated genes previously described to be involved in ESCC were identified: 
TP53, RB1, CDKN2A, PIK3CA, NOTCH1 and NFE2L2.  Furthermore, two novel genes 
not previously described to be mutated in ESCC were identified: ADAM29 and 
FAM135B.  Specifically, FAM135B mutant expression in ESCC cells was shown to 
promote malignancy (Song, Li et al.2014).  Functional studies regarding the role of the 
ADAM29 mutation in ESCC have yet to be eluded.  In addition, whole-genome 
sequencing was also able to identify significant amplification of the 11q13.3-13.4 region.  
Furthermore, this region was shown to contain MIR548K, which encodes a microRNA, 
which was shown to promote malignancy in ESCC cell lines (Song, Li et al. 2014).    
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3D organotypic culture model system  
 In order to study the progression of metaplasia to an invasive carcinoma, we 
have to make use of in vitro models to further analyze the underlying molecular 
mechanisms.  Our lab has developed an 3D organotypic culture model for the study of 
ESCC.  The use of this 3D organotypic cultures model allows for the investigation 
molecular mechanisms of epithelial-stromal interactions (Kalabis, Wong et al. 2012).    
The advantages of a 3D organotypic cultures, relate to the ability to recreate the normal 
cell polarization, differentiation cell patterns and expression of genes representative of 
those found in the in vivo tissues.  By developing a human esophageal epithelial cells 
immortalized with telomerase (hTERT) overexpression, designated as EPC2-hTERT 
cells, we are able to study the esophageal epithelium.  Our 3D organotypic cultures 
consist first of creating a “mesenchyme” layer composed of collagen I, matrigel and fetal 
embryonic fibroblast (FEF3) on which to grow the esophageal epithelial cells.  After 
seeding the epithelial cells we are able constitute a complete stratified squamous 
epithelium by exposure to a liquid-air interface (Figure 4) (Harada, Nakagawa et al. 
2003).  Through these 3D organotypic cultures we are able to recapitulate the normal 
stratification normally found in the esophageal epithelium (Kalabis, Wong et al. 2012).   
Furthermore, our 3D organotypic culture system allows for the study of cell 
signaling pathways in esophageal epithelial cells, investigation of pharmacological 
inhibitors and study of the interactions between epithelial cells and fibroblasts.  For 
examples, the expression of inducible AKT in esophageal epithelial cells shows an 
expansion of the proliferation of basal cells an impaired differentiation (Oyama, et al. 
2007).  Moreover, these epithelial cells can be transformed by the introduction of 
oncogenes (e.g., EGFR and CyclinD1) and inactivation of tumor suppressor genes 
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(mutant p53) (Grugan, Miller et al. 2010; Naganuma, Whelan et al. 2012).  Furthermore, 
this 3D organotypic cultures system can be used to study BE.  For example, our 
previous work showed overexpression of MYC and CDX1 genes lead to a partial 
transdifferentiation to BE (Stairs, Nakagawa et al. 2008).  Furthermore, studies using BE 
cell lines grown in 3D organotypic cultures have demonstrated a significant difference in 
cell morphology between BE cell lines and esophageal epithelial cells (Kosoff, Gardiner 
et al. 2011).    
Mouse models of ESCC, Barrett’s esophagus and EAC 
 Studies of ESCC development in vivo provide critical insight into the molecular 
mechanism mediating tumorgenesis in the esophagus.  Through the use of the Epstein-
Barr virus L2 promoter Cre recombinase (L2-Cre), studies have shown tissue specific 
knockout of KLF4 in the esophagus epithelium.  Moreover, these mice show increased 
basal cell proliferation and delays in differentiation.  Interestingly, these mice show early 
hypertrophy, followed by subsequent dysplasia by 6 months of age (Tetreault, Yang et 
al. 2010).  Furthermore, we have published a mouse model that can recapitulate the 
histopathology of ESCC.  This is mediated by the loss of p120catenin, specifically in the 
esophagus and oral cavity by the use of the Epstein - Barr virus L2 promoter (L2) (Stairs, 
Bayne et al. 2011).  Histological examination of L2-Cre; p120LoxP/LoxP mice reveal 
development of hyperplasia at 7-9 months of age, severe dysplasia at 9 months and 
ESCC by 12 months (Stairs, Bayne et al. 2011).  Further study of the L2-Cre ; 
p120ctnLoxP/LoxP mice show the initiation of tumorgenesis for ESCC is in part mediated by 
the infiltration of myeloid derived suppressive cells (MDSCs) (Stairs, Bayne et al. 2011).  
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In vivo studies in rodents to investigate BE and EAC currently are an active area 
of research.  One of the first in vivo models to investigate BE and EAC was in a surgical 
rodent model.  This model involves a esophagojejunostomy, which lead to the induction 
of severe reflux in the esophagus of these animals.  These rodents will develop severe 
esophagitis by 13 weeks, BE by 34 weeks and EAC by 5 months post-surgery (Pham, 
Genta et al. 2014).  Recently, new studies have shown the development of a genetic 
mouse model for BE and EAC.  In these studies the Interleukin-1β is express in the 
esophageal epithelium through the L2 promoter.  These mice at baseline show an 
inflammatory response to the expression of IL-1β by 6 months, and a late incidence of 
BE 12-15 months.  Furthermore, the addition of bile salts in the drinking water of the L2-
IL1-β mice was shown to accelerate the appearance of BE and EAC, with tumors 
observed by 15 months of age (Quante, Bhagat et al. 2012). 
 
 
 
 
 Figure 1: Normal esophageal squamous epithelium
characterized by three distinct cellular layers: basal, suprabasal and superficial 
squamous.  Each layer can be identified by expression of differential cell markers. 
cells express Keratin 5 and Keratin 14, suprabasal cell
13, and superficial squamous express involucrin, profilaggrin and desmocollins.   
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19 
rcinoma (ESCC)
 
 
esophageal 
.   List of 
 Figure 4: 3D organotypic culture m
collagen layer, followed by addition of 
After culture for 7 days, the epithelial cells are seeded on the surface of 
matrix.  After culture for additi
promoting epithelial cell stratification and differentiation.  Finally, on day 15 the 3D 
organotypic cultures are harvested for histology.  
   
20 
odel system.  Day 0: placement of acellular 
collagen, matrigel and esophageal fibroblast
onal 4 days, cells are exposed to an air-liquid interface
 
 
s.  
the contracted 
, 
21 
 
 
 
Chapter II:  
Inhibition of Notch signaling enhances 
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Abstract  
Barrett’s esophagus (BE) is defined as an incomplete intestinal metaplasia 
characterized by the presence of columnar and goblet cells in the formerly stratified 
squamous epithelium of the esophagus.  BE is a documented precursor of esophageal 
adenocarcinoma.  Currently, there is no clearly identified cell of origin for human BE and 
our interest is to understand how squamous epithelial cells may evolve to BE.  To that 
end, we have investigated the role of Notch signaling in the development of BE.  Notch 
signaling was inhibited in human esophageal epithelial cells by expression of dominant-
negative-Mastermind-like (dnMAML) and potential cell transdifferentiation was assessed 
by 3D organotypic culture with evaluation of BE-lineage specific gene expression. 
Furthermore, KLF4 and HATH1 knockdown was in order to determine if the observed 
phenotype could be rescued following Notch inhibition.  Data from our RNA microarray 
revealed that BE samples expressed lower levels of Notch receptors (NOTCH2 and 
NOTCH3) and the ligand (JAG1).  Furthermore, a BE tissue microarray showed 
decreased NOTCH1 expression and the Notch signaling downstream target HES1.  
Notch inhibition promoted partial transdifferentiation of esophageal epithelial cells 
towards columnar-like cells as demonstrated by increased expression of columnar 
keratins and glandular mucins and decreased expression of squamous keratins.  In 3D 
culture, elongated cells were observed in the basal layer of the epithelium with Notch 
inhibition.  Importantly, knockdown of KLF4 reversed partially the effects of Notch 
inhibition.  A partial reversal was observed as well with HATH1 knockdown.  Thus, Notch 
signaling inhibition promotes transdifferentiation of esophageal cells towards BE-like 
metaplasia in part via upregulation of KLF4 and HATH1, representing a novel 
mechanism underlying the potential initiation of BE. 
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Introduction  
Barrett’s esophagus (BE) is defined as an incomplete intestinal metaplasia of the 
esophagus.  BE is classically characterized by the presence of differentiated intestinal 
columnar cells and mucin-producing goblet cells.  BE is estimated to have a prevalence 
of 5-6% in the US (Fitzgerald 2006; Hayeck, Kong et al. 2010).  Gastroesophageal reflux 
disease (GERD), abdominal obesity, cigarette-smoking and Helicobacter pylori (H.pylori) 
infection eradication have been linked as risk factors associated with the development of 
BE (Fitzgerald, 2006).  Furthermore, the local pro-inflammatory microenvironment plays 
a critical role in the initiation and maintenance of BE (Fitzgerald, 2006; Reid, Li et al. 
2010).  BE can progress to low-grade dysplasia, high-grade dysplasia and culminate in 
the development of esophageal adenocarcinoma (EAC).  It is estimated that 0.5% of BE 
patients will develop EAC, and this risk increases to 10% in BE patients with high-grade 
dysplasia (Hayeck, Kong et al. 2010).  
In 2013, an estimated 17,990 patients were diagnosed in the US with esophageal 
cancer, both EAC and esophageal squamous cell carcinoma (ESCC).  Esophageal 
cancer is one of the deadliest cancers in the US with a 5-year survival rate of 17.3% in 
2013 (Howlader, Noone et al. 2013).  Therefore, studying the molecular mechanisms 
underlying the pathogenesis of BE could provide novel biomarkers or prognostic 
indicators for both BE and EAC patients.  The study of BE has been limited historically to 
human biopsy samples, which have been used to analyze histopathological and genetic 
changes.  Some of the known changes occurring in BE are the methylation and loss of 
heterozygosity (LOH) of p16 and also LOH of p53 (Graham and McDonald 2010).  A 
mosaic pattern of genetic alterations can be found in human biopsy samples, 
complicating the identification of the initiating genetic changes that lead to BE.  
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There have been several hypotheses proposed for the cell of origin of BE 
(DeVault, McMahon et al. 2013).  These include: (1) transdifferentiation of cells from the 
esophageal basal layer or from the ducts of esophageal submucosal glands, (2) 
migration of cells located at the esophago-gastric junction or of the gastric cardia cells 
and (3) bone marrow derived progenitor cells (Quante, Bhagat et al 2012; Sarosi, Brown 
et al. 2008; Wang, Ouyang et al. 2011).  
Recent studies have undertaken a genetic approach to investigate the initiating 
events that lead to the development of BE.  Through this approach, two genes, CDX1 
and MYC (c-Myc), have been identified by our group to have a role in the potential 
development of BE (Stairs, Nakagawa et al. 2008).  CDX1 is part of the caudal 
homeobox family of transcription factors (CDX1 and CDX2), which are important in the 
development and differentiation of the small intestine and colon (Guo, Suh et al. 2004).  
In fact, conditional knockout of Cdx2 in the intestine of the mouse results in squamous 
metaplasia (Gao, White et al. 2009).   
MYC is a transcription factor known to bind to E-box sequences and can activate 
approximately 15% of all genes in the human genome (Herold, Herkect et al. 2009; 
Meyer and Penn 2008).  MYC is overexpressed in many cancers, including EAC, 
through gene amplification (Ruggero 2009; von Rahden and Stein 2006).  MYC is 
involved in the activation and regulation of a variety of cellular processes such as cell 
cycle progression, cell differentiation, energy metabolism, angiogenesis and DNA 
damage repair (Meyer and Penn 2008).  Our microarray analysis of BE samples 
revealed that negative regulators of MYC, namely MXI1 and MXD1, were 
downregulated, while certain MYC target genes ODC1 and CA2 were increased (Stairs, 
Nakagawa et al. 2008), suggesting that MYC signaling is active in BE.  In addition, the 
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microarray data showed increased CDX1 and CDX2 expression in BE (Stairs, 
Nakagawa et al. 2008).  Our previous studies using a human esophageal epithelial cell 
line immortalized with hTERT (EPC2-hTERT) have allowed us to study human 
esophageal epithelial biology (Harada, Nakagawa et al. 2003).  Our previous data have 
shown that CDX1 overexpression together with MYC in the EPC2-hTERT cells can lead 
to a partial change towards BE (Stairs, Nakagawa et al. 2008).  The partial change 
toward BE suggests the need to explore additional genetic changes in the context of 
MYC and CDX1. 
Interestingly, loss of Notch signaling is required for the differentiation of the 
goblet cell lineage in the small intestine (van Es, van Gijn, et al. 2005; Fre, Huyghe et al. 
2005).  In addition, inhibition of Notch signaling in the small intestine by either γ-
secretase inhibitor (GSI), or conditional knockout of Rbpj, can lead to goblet cell 
hyperplasia (van Es, van Glin et al. 2005; Fre, Huyghe et al. 2005; Menke, van Es et al. 
2010).  The Notch signaling pathway comprises four homologous transmembrane Notch 
receptors (NOTCH1-NOTCH4) that can be activated by transmembrane ligands, Delta 
or Jagged, generally expressed by neighboring cells (La Voie and Selkoe 2003, 
Benedito, Roca et al. 2009).  Upon ligand binding, Notch receptors undergo cleavage by 
ADAM-family metalloproteases at the extracellular domain and by γ-secretase at the 
intracellular domain (La Voie and Selkoe 2003).  These events lead to the release of the 
intracellular Notch domain (ICN) allowing its nuclear translocation, binding to RBPJ and 
activation of Notch target genes, such as HES1 and HES5 (La Voie and Selkoe 2003; 
Ntziachristos, Lim et al. 2014).  Interestingly, Notch is known to be involved in cell fate 
decisions in several cell types including lymphocytes, neurons, skin and others 
(Ntziachristos, Lim et al. 2014).   
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Previous studies have shown Notch signaling can regulate intestinal cell 
differentiation, mediated through the negative regulation of KLF4 and HATH1.  KLF4 and 
HATH1 are critical transcription factors required for proper differentiation of the secretory 
lineage in the context of the small intestine.  Notch signaling can be a negative regulator 
of Krüppel-like factor 4 (KLF4) expression in the small intestine (Zheng, Pritchard et al. 
2009).  Indeed, it has been demonstrated previously that the KLF4 promoter contains 
ICN responsive elements, through which Notch can inhibit KLF4 expression (Zheng, 
Pritchard et al. 2009; Ghaleb, Aggarwal et al. 2008).  KLF4 is part of a family of DNA-
binding transcription factors that has been shown to play a role in multiple processes 
from proliferation, cell differentiation, inflammation and pluripotency (McConnell and 
Yang 2010).  Recently, high KLF4 expression was reported in human BE biopsies; it was 
also shown that its promoter is activated by bile acid (Kazumori, Ishihara et al. 2011).  In 
addition, KLF4 can increase the transcriptional activity of MUC2 and CDX2, suggesting a 
potential role in BE development (Kazumori, Ishihara et al. 2011).   
HATH1 (Atonal homolog 1 or ATOH1) is a basic helix-loop-helix transcription 
factor that is known to be important for the differentiation of secretory cells in the small 
intestine (Shroyer, Helmrath et al. 2007).  Math1-/- (mouse homolog of HATH1) mice lack 
goblet and other secretory cells in the small intestine and die shortly after birth (Yang, 
Bermingham et al. 2001).  Previous studies have shown a possible inverse relationship 
between Math1 expression and Notch activity in the small intestine (Kazanjian, Noah et 
al. 2010).  It is believed that HES1 can downregulate HATH1 expression (Kazanjian, 
Noah et al. 2010).  This negative regulation of Math1 leads to a selection pressure 
towards the enterocyte lineage, while cells with low Notch and low Hes1 will have more 
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Math1 and differentiate towards the secretory lineage (Yang, Bermingham et al. 2001; 
Suzuki, Fukui et al. 2005).  
In this study, we utilize an innovative three-dimensional (3D) organotypic culture 
model system to demonstrate that the cooperation of MYC, CDX1, and Notch signaling 
inhibition results in a switch of cell identity and lineage specification from the normal 
esophageal squamous epithelium to a BE-like metaplasia mediated through KLF4 and 
HATH1.  Our data support the novel paradigm in which transdifferentiation of 
esophageal basal cells lead to initiation of BE.    
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Results 
Notch signaling is downregulated in human Barrett’s esophagus  
In order to investigate the status of Notch signaling in Barrett’s esophagus (BE), 
we performed a RNA microarray on human BE biopsies compared to adjacent normal 
squamous esophagus (GEO accession # GSE 13083) (Stairs, Nakagawa et al. 2008).  A 
significant decrease in expression of NOTCH2 and NOTCH3 receptors by 4- and 2-fold 
respectively, was observed in BE versus paired normal squamous esophagus.  
Expression of the Notch ligand JAG1 was also decreased by 3-fold, thereby suggesting 
a potential downregulation of Notch signaling in BE (Figure 1A).  We next performed IHC 
of human BE (n=15-23) and normal esophagus (n=25-27) tissue microarray (TMA) for 
NOTCH1 receptor, the active form of NOTCH1, ICN1 and its key downstream target the 
transcription factor HES1 (Figure 1B-C).  We observed positive nuclear staining for 
HES1 and NOTCH1 restricted to the basal layer of normal esophageal epithelium, 
whereas ICN1 showed more diffused cytoplasmic staining (Figure 1B).  In BE, we 
observed a loss of nuclear HES1 staining and loss of nuclear and membranous 
NOTCH1, and decreased ICN1 staining (Figure 1B).  The TMA was scored for intensity 
of staining (Supplemental Table 1).  HES1, NOTCH1 and ICN1 protein expression is 
decreased significantly in BE when compared to normal esophagus (Figure 1C).  Thus, 
data from both RNA microarray and TMA suggest that Notch signaling is downregulated 
in BE compared to the normal esophageal epithelium, suggesting Notch signaling may 
be required as well for maintenance of the normal esophageal squamous epithelium. 
Inhibition of Notch signaling induces morphological changes in esophageal 
epithelial cells 
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Next, we proceeded to inhibit Notch signaling in the context of MYC and CDX1. 
We infected EPC2-hTERT-MYC-CDX1 (MYC-CDX1) cells with a construct encoding for 
dominant-negative Mastermind-like (dnMAML) to inhibit Notch signaling (MYC-CDX1-
dnMAML cells).  We confirmed expression of dnMAML-GFP tagged protein by western 
blotting using a GFP specific antibody (Figure 2A).  To verify Notch signaling abolition 
following dnMAML overexpression, we used an 8X-CSL-Luciferase reporter construct, 
which upon expression of ICN1 can activate luciferase expression.  We observed a 
significant inhibition of nearly 10-fold in the presence of dnMAML (MYC-CDX1-dnMAML-
ICN1 cells) compared to MYC-CDX1-ICN1 (Figure 2B).  We confirmed also 
downregulation of Notch target gene expression by dnMAML via quantitative PCR 
(qPCR).  Indeed, we observed a significant decrease of HES1 (3.3-fold) and HES5 
(12.5-fold) expression in MYC-CDX1-dnMAML when compared to MYC-CDX1 cells 
(Figure 2C).  These results support that dnMAML overexpression is sufficient to inhibit 
Notch signaling. 
We next used 3D organotypic cultures to analyze changes in cell morphology 
and differentiation (Kalabis, Wong et al. 2012).  We observed that MYC-CDX1-dnMAML 
cells formed a thinner stratified epithelium than MYC-CDX1 cells, suggesting disruption 
of normal differentiation.  We also noted that MYC-CDX1-dnMAML 3D cultures showed 
an altered cell morphology in the basal layer (Figure 2D), when compared to MYC-CDX1 
cells.  In order to further characterize these changes in the basal layer, we performed 
electron microscopy of MYC-CDX1 and MYC-CDX1-dnMAML cultures (Figure 2E).  We 
observed an elongation of MYC-CDX1-dnMAML basal cells when compared to MYC-
CDX1 cells, consistent with acquisition of a columnar-like morphology.  Indeed, basal 
cellular height was significantly increased (1.4-fold) in 3D cultures overexpressing 
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dnMAML (Figure 2F) compared to MYC-CDX1.  These changes in cell morphology in 
the basal layer in MYC-CDX1-dnMAML cells suggest that the inhibition of Notch 
signaling may promote transdifferentiation of normal esophageal epithelium towards a 
more columnar-like epithelium.  
Inhibition of Notch signaling induces a switch from squamous to columnar gene 
expression 
We analyzed further our 3D cells to investigate if morphological changes 
observed in MYC-CDX1-dnMAML cells reflect changes in lineages.  We conducted 
immunohistochemistry (IHC) for the squamous keratin 13 (K13). In MYC-CDX1 cells, we 
observed strong staining for K13 in the suprabasal region, whereas staining was 
reduced significantly in MYC-CDX1-dnMAML cells.  Conversely, we observed increased 
staining of columnar keratin 19 (K19) in both the basal and suprabasal compartment in 
MYC-CDX1-dnMAML cells compared to MYC-CDX1 cells (Figure 3B).  
We next used qPCR to evaluate additional squamous and columnar lineage 
specific keratins in MYC-CDX1-dnMAML cells.  Prior to this, cells were grown in the 
presence of calcium (0.6 mmol/L) for 48 hrs to allow squamous differentiation (Ohashi, 
Natsuizaka et al. 2010).  We observed that MYC-CDX1-dnMAML cells expressed 
reduced levels of squamous keratins: K5 (5-fold) K13 (16.6-fold) and K14 (5-fold) (Figure 
4A).  Furthermore, MYC-CDX1-dnMAML cells expressed higher levels of columnar 
keratins: K8 (2.2-fold), K18 (2.8-fold), K19 (1.9-fold) and K20 (2.8-fold) compared to 
MYC-CDX1 cells (Figure 4B).  These results suggest that inhibition of Notch signaling 
via dnMAML promotes a switch in gene expression from squamous to columnar 
keratins.  Furthermore, since BE is often characterized by the presence of goblet cells in 
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the esophageal epithelium, we next investigated expression of mucins, the major protein 
family secreted by this cell type. Interestingly, we observed increased levels of MUC2 
(10.4-fold), MUC3B (21.5-fold), MUC5B (305-fold) and MUC17 (116.3-fold) in MYC-
CDX1-dnMAML cells when compared to MYC-CDX1 cells (Figure 4C).  Thus, inhibition 
of Notch signaling fosters expression of goblet cell lineage specific genes.  Finally, we 
quantified the expression of the squamous differentiation genes desmocollin1 and 
desmocollin3 (DSC1, DSC3).  We observed that dnMAML overexpression in MYC-CDX1 
cells decreased significantly DSC1 (20-fold) and DSC3 (3.7-fold) expression (Figure 4D).  
Taken together, these data support the premise that inhibition of Notch signaling in 
cooperation with MYC and CDX1 may orchestrate a genetic switch from a squamous 
cell lineage to an intestinal columnar cell lineage.  
Inhibition of Notch signaling mediates transdifferentiation to a BE-like metaplasia 
via a HES1 independent manner  
Classically, Notch signaling leads to activation of transcriptional factors such as 
HES1 and HES5.  In the intestine, HES1 has been shown to be a negative regulator of 
HATH1, thereby promoting absorptive cell fate over secretory cell fate (Zheng, Shou et 
al. 2000; Kazanjian, Noah et al. 2010).  Therefore, we investigated if downregulation of 
HES1 could mimic the results obtained with dnMAML overexpression in MYC-CDX1 
cells.  We performed stable knockdown of HES1 with two independent shRNA 
constructs (shHES1 #1 and shHES1 #2) in MYC-CDX1 cells (Supplemental Figure 1A). 
We did not observe any changes in squamous and columnar keratins or in mucin genes 
expression upon knockdown of HES1 suggesting that HES1 alone is not sufficient to 
transdifferentiate esophageal epithelial cells (Supplemental Figure 1B-D).  We observed 
a trend of upregulation of HATH1 expression validating the functional HES1 knockdown 
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(Supplementary Figure 1E).  Thus, HES1 knockdown could not recapitulate the effects 
of Notch signaling inhibition suggesting that Notch might act via other downstream 
targets to regulate transdifferentiation to BE. 
HATH1 knockdown leads to partial reversal of the transcriptional changes 
following Notch signaling inhibition 
Previous studies have shown a possible inverse relationship between Math1 
expression and Notch activity in the context of the small intestine.  It is believed that 
HES1 can downregulate HATH1 expression (Kazanjian, Noah et al. 2010).  Interestingly, 
HATH1 expression is increased 58-fold in MYC-CDX1-dnMAML cells (Figure 5A) as 
observed by qPCR.  We were unable to detect HATH1 via Western blotting (data not 
shown).  Thereby, we investigated HATH1 as a possible mediator of the effects 
observed by Notch signaling inhibition in the MYC-CDX1-dnMAML cells.  Using stable 
lentiviral infection, we achieved HATH1 knockdown of 2.6-fold in the MYC-CDX1-
dnMAML cells (Figure 5B).  Analysis of columnar keratins expression showed a 
significant decrease of K8, a decreased trend of K20 and no change for K18 and K19 in 
the MYC-CDX1-dnMAML-shHATH1 cells (Figure 5C).  We observed a significant 
decrease for MUC2, but no changes in MUC3B, MUC5B and MUC17 (Figure 5D).   
Interestingly, we observed a significant increase of the squamous keratins K5, K13 and 
K14 in the MYC-CDX1-dnMAML-shHATH1 cells (Figure 5E).  We also observed an 
increased expression of DSC1 and DSC3, upon HATH1 knockdown (Figure 5F).  
Furthermore, analysis of MYC-CDX1-dnMAML-shHATH1 cells in 3D cultures show no 
changes in cell morphology (data not shown).  Taken together, these results 
demonstrate that HATH1 may partially mediates the transdifferentiation to a BE-like 
metaplasia promoted through Notch signaling inhibition.  
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KLF4 knockdown reverses the morphological and transcriptional changes 
following Notch signaling inhibition  
Active Notch signaling mediated by ICN1 downregulates KLF4 expression in the 
intestinal epithelium (Ghaleb, Aggarwal et al. 2008).  Conversely, inhibition of Notch 
signaling via GSI can cause upregulation of KLF4 expression (Zheng, Pritchard et al. 
2009).  Interestingly, KLF4 expression is increased in MYC-CDX1-dnMAML cells when 
compared to MYC-CDX1 cells (Figure 6A, 6B).  Therefore, we investigated whether 
KLF4 knockdown in MYC-CDX1-dnMAML cells could reverse the morphological 
changes observed following dnMAML overexpression.  Using stable lentiviral infection, 
we achieved significant knockdown of KLF4 using 2 independent shRNA sequences in 
MYC-CDX1-dnMAML cells (Figure 6C, 6D).  We observed the highest degree of KLF4 
knockdown in the MYC-CDX1-dnMAML-shKLF4 #3 (3.3-fold in RNA and 25-fold in 
protein) cells.  Stable KLF4 knockdown results in a decrease of elongated (columnar-
like) cells observed with Notch signaling inhibition in 3D culture (Figure 6E).  
Furthermore, cells at the basal layer of the epithelium have a more cuboidal shape, 
suggesting that inhibition of KLF4 in the MYC-CDX1-dnMAML cells may reverse 
morphological changes observed with Notch signaling inhibition.   
Analysis of columnar lineage specific keratins showed significantly decreased K8 
and K20 expression, but no changes in K18 and K19 in MYC-CDX1-dnMAML-shKLF4 
cells (Figure 7A).  We also observed a significant decrease in MUC2 and MUC5B 
expression, but no changes in MUC3B and MUC17 (Figure 7B).  Furthermore, we 
evaluated expression of the squamous keratins K5, K13 and K14 in MYC-CDX1-
dnMAML-shKLF4 cells and MYC-CDX1-dnMAML-shScramble cells.  KLF4 knockdown 
significantly increased expression of K5, K13 and K14, supporting the premise that KLF4 
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knockdown can partially reverse the switch from squamous to columnar keratins 
observed with Notch signaling inhibition (Figure 7C).  Moreover, expression of the 
squamous differentiation marker DSC1 is increased significantly in MYC-CDX1-
dnMAML-shKLF4 cells (Figure 7D).  Overall, these results demonstrate that dnMAML-
induced transdifferentiation may be in part mediated by KLF4.  Taken together, our data 
demonstrate a novel function for Notch signaling in BE development mediated by KLF4 
and HATH1.  Importantly, this supports the model in which esophageal epithelial basal 
cells might serve as a potential the cell of origin for Barrett’s esophagus metaplasia in a 
3D organotypic culture model system. 
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Discussion  
Barrett’s esophagus (BE) is defined as an incomplete intestinal metaplasia of the 
esophagus, and the biological mechanisms underlying its development remain to be 
clarified.  Herein, we demonstrate that Notch signaling is downregulated in human BE, 
suggesting that development of intestinal metaplasia in the esophagus could require 
inhibition of Notch signaling.  Indeed, inhibition of Notch promotes the initial phases of 
transdifferentiation in our model system.  First, there is the appearance of elongated 
columnar-like cells in the basal layer of 3D organotypic cultures in response to Notch 
inhibition.  Second, there is a switch in genes that denote the squamous versus BE 
lineages, characterized by a diminution of squamous keratins and differentiation markers 
in favor of an induction of columnar keratins and mucins.  These results suggest that the 
combination of Notch inhibition and MYC and CDX1 overexpression may promote 
transdifferentiation of esophageal epithelial cells towards BE metaplasia. 
Transdifferentiation may be viewed as lineage reprogramming, involving a 
process where one somatic cell switches into another somatic cell without undergoing an 
intermediate pluripotent or progenitor cell type (Orkin and Zon  2008; Graf and Enver 
2009).  The cell of origin for development of BE remains the subject of investigation, but 
transdifferentiation of esophageal stratified epithelium is one of the proposed models 
(DeVault, McMahon, et al. 2013).  One study of human BE biopsies has revealed that 
esophageal cells undergo a transition of expression of intestinal markers like CDX2 and 
MUC5AC (Hahn, Blount et al. 2009).  Interestingly, NOTCH1 activation is observed at 
the onset of squamous differentiation of the esophageal epithelium.  NOTCH1 and 
NOTCH3 orchestrate transcriptional regulation of early differentiation markers in a CSL-
dependent manner (Ohashi, Natsuizaka et al.2010).  Perturbation of esophageal 
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squamous differentiation is notably observed following loss of Notch signaling in the 
esophageal epithelium (Ohashi, Natsuizaka et al.2010).  Notch signaling orchestrates 
cell differentiation in several tissues.  Furthermore, loss of Notch signaling is required for 
the differentiated goblet cells and other secretory cell lineages in the small intestine (van 
Es, van Gijn et al. 2005; Fre, Huyghe et al. 2005).   
We show that the combination of Notch inhibition with MYC and CDX1 
overexpression leads to characteristic features of BE, namely the production of mucin by 
goblet-like cells and the presence of columnar-like cells.  It was suggested previously 
that HATH1 induction by Notch inhibition induces MUC2 via CDX2 expression in 
esophageal cancer cell lines (Tamagawa, Ishimura et al. 2012).  Moreover, goblet cell 
differentiation was induced by Notch inhibition in the L2-IL-1β mouse model of Barrett’s-
like metaplasia (Quante, Bhagat et al. 2012).  Hence, Notch signaling inhibition could be 
necessary for the initiation of the BE metaplasia program by orchestrating transcriptional 
regulation of key genes implicated in goblet cell terminal differentiation.  
Previous studies have shown a possible inverse relationship between HATH1 
expression and Notch activity in the small intestine.  This regulation has been suggested 
to be mediated by HES1 (Kazanjian, Noah et al. 2010).  Furthermore, studies of BE cell 
lines treated with bile acid show decrease Notch expression accompanied by HATH1 
and CDX2 upregulation (Morrow, Avissar et al. 2009).  Interestingly, our MYC-CDX1-
dnMAML cells show increased HATH1 expression, supporting the premise that Notch is 
a negative regulator of HATH1.  Yet, our HATH1 knockdown data only shows a partial 
reversal of the gene expression changes observed upon Notch signaling inhibition in the 
MYC-CDX1 cells.  Moreover, HATH1 knockdown had no effect in the changes in cell 
morphology observed in the MYC-CDX1-dnMAML cells.  Thus, our data suggest HATH1 
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is a limited mediator of the transdifferentiation process induced by Notch signaling 
inhibition.  
KLF4 can be regulated negatively by Notch signaling (Zheng, Pritchard et al. 
2009).  Herein, we demonstrate that inhibition of Notch signaling causes an activation of 
KLF4 expression and that knockdown of KLF4 can reverse some of the genetic and 
morphological changes induced by Notch signaling inhibition.  These data support KLF4 
as a potential driver in the activation of intestinal cell lineage genes upon Notch signaling 
inhibition, suggesting a possible novel mechanism through which Notch signaling 
promotes initiation of BE development.  Interestingly, KLF4 is strongly expressed in 
Barrett’s esophagus and its expression is induced in response to bile acids.  KLF4 and 
CDX2 also cooperate to induce production of MUC2.  Interestingly, KLF4 has been 
linked to other models of transdifferentiation, including conversion of smooth muscle 
cells into osteogenic cells in the context of hyperphosphatemia and conversion of 
fibroblasts into neural progenitors or cardiomyocytes (Yoshida, Yamashita et al. 2012; 
Kim, Efe, et al. 2011; Efe, Hilcove et al. 2011).  KLF4 is one of the key factors (OCT4, 
SOX2, MYC, NANOG and KLF4) that can reprogram the fate of somatic cells into 
inducible pluripotent stem cells (iPSC).  KLF4 is also recognized for its capacity to 
maintain the pluripotent state of embryonic stem cells (ESC) (McConnell and Yang 
2010).  Therefore, KLF4 activation in response to Notch inhibition could facilitate 
transdifferentiation of esophageal squamous cells into intestinal-like cells by binding to 
promoters of columnar keratins and mucin genes to enhance their expression (Figure 8).   
Herein, we provide evidence to support the notion that esophageal basal cells 
might serve as potential cells of origin for BE.  Several models of the cell of origin for BE 
have been proposed.  These are not necessarily mutually exclusive and may be context 
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dependent.  One model suggests that cells may migrate from the esophago-gastric 
junction (EGJ) or from the gastric cardia to the distal esophagus (Quante, Abrams et al. 
2012).  By lineage-labeling gastric cardia stem cells (LGR5+) cells in L2-IL-1β transgenic 
mice that develop BE and EAC, it was demonstrated that migration of gastric cardia cells 
give rise to BE tissue (Quante, Bhagat et al. 2012).  It is also possible that bone marrow 
derived progenitor cells give rise to BE.  Indeed, male to female bone marrow 
transplants in a severe reflux esophagitis rat model showed that the developing BE 
epithelium was of male origin (Sarosi, Brown et al. 2008), suggesting that progenitor 
cells originating from the bone marrow can contribute to BE development.  
Metaplasia may represent an adaptive response to a stressful local environment, 
and involve a complex interplay between epigenetic and genetic factors or alterations.  It 
can occur in several tissues including esophagus (BE), stomach, pancreas, lung, cervix 
and skin.  Metaplasia may be reversible or irreversible, and may progress to dysplasia 
and cancer.  For example, BE can progress to low-grade and high-grade dysplasia and 
culminate in esophageal adenocarcinoma (EAC).  Our studies suggest cell autonomous 
mechanisms involving Notch signaling and pivotal transcription factors: MYC, CDX1, 
HATH1 and KLF4, which promote a partial reprogramming of the esophageal cells 
toward BE.  However, the complete emergence of BE, and certainly progression to a 
dysplastic state and EAC may involve cell non-autonomous mechanisms, such as 
inflammation and activation of Hedgehog signaling and Wnt signaling (Fang, Chen et al. 
2013; Clement, Guilleret et al. 2008; Yang, Wang et al. 2012).  In summary, we now 
demonstrate key mechanisms underlying the initiation of BE, which holds the potential 
for future biomarker studies for patients at risk for progression to EAC.  
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Methods 
Cell lines 
EPC2-hTERT-MYC-CDX1 cells and their derivatives: EPC2-hTERT-MYC-CDX1-
dnMAML, EPC2-hTERT-MYC-CDX1-dnMAML-shKLF4, EPC2-hTERT-MYC-CDX1--
dnMAML-shHATH1, EPC2-hTERT-MYC-CDX1-dnMAML-shScramble, EPC2-hTERT-
MYC-CDX1-shHES1 and EPC2-hTERT-MYC-CDX1-shScramble were grown in KSFM 
(Keratinocyte Serum Free Medium, Invitrogen Carlsbad, CA) with Ca2++ and 
supplements: BPE (bovine pituitary extract), EGF and 1% Penicillin Streptomycin 
(Invitrogen), as described previously (Harada, Nakagawa et al. 2003).  Cells were 
treated with 0.06 mmol/L calcium chloride (Ca2++) to promote squamous differentiation 
for 48 hrs before harvesting RNA. Phoenix A cells were grown in DMEM (Invitrogen, 
Carlsbad, CA) with 10% FBS (Sigma, St. Louis, MO) and 1% Penicillin Streptomycin.  
FEF3 cells (fetal embryonic fibroblasts) were grown in DMEM supplemented with 10% 
HyClone FBS (GE Healthcare Life Sciences, Piscataway, NJ) and 1% Penicillin 
Streptomycin, as described previously (Grugan, Miller et al. 2010).     
Stable transduction 
MYC-CDX1 cells were transduced with pBabe-puro or pBabe-dnMAML-GFP-puro or 
pBabe-zeo, pBabe-dnMAML-GFP-zeo virus.  MYC-CDX1 cells were also transduced 
with pLKO.1 shScramble-puro or pLKO.1 TRC puro-shHES1 virus.  MYC-CDX1-
dnMAML (zeo) cells were transduced with pLKO.1 shScramble-puro, pLKO.1 shKLF4 or 
pLKO.1 shHATH1 virus.  Transduced cells were selected with 1ug/ml puromycin (EMD-
Millipore, Billerica, CA), or 10ug/ml zeocin (Invitrogen, Carlsbad, CA) for 7 days. 
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3D Organotypic culture  
EPC2-hTERT-MYC-CDX1 cells and their derivatives were grown using the 3D 
organotypic culture system as described previously (Kalabis, Wong et al. 2012).  
Cultures were fixed overnight in 10% buffered formalin phosphate (Fisher, Waltham, 
MA) before paraffin embedding and sectioning.  
 Histology and Immunohistochemistry  
Hematoxylin and eosin (H&E) staining as well as immunohistochemistry (IHC) were 
performed as described previously (Stairs, Nakagawa et al. 2008).  The following 
antibodies were used for IHC: K13 (Abcam, Cambridge, MA) 1:500, K19 (BioLegend, 
San Diego, CA) 1:100, HES1 (Abcam, Cambridge, MA) 1:500, NOTCH1 (Epitomics, 
Burlingame, CA) 1:100 and ICN1 (Cell Signaling, Beverly, MA) 1:200.  Biotinylated 
secondary antibodies (Jackson Immunoresearch Laboratories Inc., West Grove, PA) and 
ABC avidin-biotin-DAB detection kit (Vector Labs, Burlingame, CA) were used for 
detection and visualization according to supplier’s protocol. 
Cell height measurement  
Quantification of cell height at the basal layer of MYC-CDX1 and MYC-CDX1-dnMAML 
cells grown in 3D organotypic cultures was performed by measuring 15 cells per HPF 
(high power field) of H&E (n=360).  We measured 4 independent 3D organotypic 
cultures for each cell line.  Statistical analysis for significance was determined by student 
t-test with p<0.05 as statistically significant.  
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Tissue Microarray 
Tissue microarray (TMA) of human biopsies of Barrett’s esophagus (n=15-23), normal 
esophagus (n=25-27) and liver control were stained for status of Notch signaling.  IHC 
staining of TMA was performed using the following antibodies: HES1, NOTCH1 and 
ICN1.  Scoring for positive staining of HES1, ICN1 and NOTCH1 was analyzed by 
quantitative evaluation of staining intensity with a scale of 0-2 (0=none to 2=strong), by a 
pathologist (Andres Klein-Szanto) in a blind manner.   
Statistical Analysis 
For gene expression changes in qPCR studies, statistical significance of comparisons 
between MYC-CDX1 and MYC-CDX1-dnMAML cells and between MYC-CDX1-
dnMAML-shScramble and MYC-CDX1-dnMAML-shKLF4 cells were determined by the 
student t-test with p<0.05 as statistically significant.  Error bars represent the mean ± 
SEM (Standard Error of the Mean) from at least triplicate experiments.  Scoring data of 
TMA was analyzed for statistical significance by Fisher’s Exact Test with p<0.05 as 
statistically significant.  
Retroviral and lentiviral production 
Retroviral productions for the following vectors (pBabe-puro and pBabe-dnMAML-GFP-
puro, pBabe-zeo, pBabe-dnMAML-GFP-zeo) were performed using Phoenix A cells as 
described previously (Okawa, Michaylira, et al. 2007).  Lentiviral production of 10µg 
pLK0.1 shRNA constructs was performed in 293T cells with pLKO.1 shScramble-puro, 
pLKO.1 TRC puro-shHES1 or pLKO.1 TRC puro-shKLF4 in combination with 6µg 
pPAX2 and 3µg pMD2.G.  For both retroviral and lentiviral production, cells were 
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transfected using the Calcium Phosphate transfection protocol, as described previously 
(Pear, Scott, et al. 1997).  Viral supernatants were harvested using a low serum DMEM 
containing 5% FBS at 48 and 72 hours post-transfection and stored at -80C. 
shRNA constructs  
Constructs were made following the AddGene protocol for the pLKO.1 TRC puro cloning 
strategy for adding shRNA to the lentiviral vector (Moffat, Grueneberg et al. 2006).  
Sequences used for oligos in Methods Table 1.  
Methods Table 1: shRNA constructs oligos 
shRNA 
CONSTRUCT FORWARD OLIGO REVERSE OLIGO 
shHATH1 #1  
CCGGAACTTCCAGCAAACAG
GTGAATTCTCGAGTTCACCT
GTTTGCTGGAAGTTTTTTTG 
AATTCAAAAAAACTTCCAGC
AAACAGGTGAATTCTCGAG
TTCACCTGTTTGCTGGAAGT
T 
shKLF4 #1 
CCGGAAGGACTTTATTCTCT
CCAATTTCTCGAGATTGGAG
AGAATAAAGTCCTTTTTTTG 
AATTCAAAAAAAGGACTTTA
TTCTCTCCAATTTCTCGAGA
TTGGAGAGAATAAAGTCCTT 
shKLF4 #3 
CCGGAACCTTACACATGAAG
AGGCATTCTCGAGTGCCTCT
TCATGTGTAAGGTTTTTTTG 
AATTCAAAAAAACCTTACAC
ATGAAGAGGCATTCTCGAG
TGCCTCTTCATGTGTAAGGT
T 
shHES1 #1 
CCGGAACAACACGACACCG
GATAAAAATTCTCGAGTTTAT
CCGGTGTCGTGTTGTTTTTT
TG 
AATTCAAAAAAACAACACGA
CACCGGATAAAAATTCTCGA
GTTTATCCGGTGTCGTGTT
GTT 
shHES1 #2 
CCGGAAGCTCTGAAGAAAGA
TAGCTTTCTCGAGAGCTATC
TTTCTTCAGAGCTTTTTTTG 
AATTCAAAAAAAGCTCTGAA
GAAAGATAGCTTTCTCGAG
AGCTATCTTTCTTCAGAGCT
T 
 
43 
 
Luciferase Assay  
Cells were seeded into 24-well plates 24 hrs before transfection at a concentration of 
1.5x105 cells per well and transfected using Lipofectamine LTX with PLUS Reagent 
(Invitrogen, Carlsbad, CA) according to manufacturer’s protocol.  The following vectors 
were used for transfection: 0.2µg pGL3-8XCSL (Ohashi, Natsuizaka et al. 2010), 0.01µg 
pRL-SV40 and 0.2µg MigRI or MigRI-ICN1.  Transfected cells were harvested 24 hrs 
post-transfection for measurement of luciferase activity using the Dual Luciferase Assay 
Kit (Promega, Madison, WI) and following the manufacturer’s protocol.  
RNA extraction and quantitative PCR  
Total RNA was extracted using the RNeasy Kit (Qiagen, Germantown, MA) according to 
the manufacturer’s protocol.  First strand cDNA synthesis was performed using the 
SuperScript First Strand Synthesis Kit (Invitrogen, Carlsbad, CA). Real‐Time PCR was 
performed and analyzed using the StepOnePlus Real-Time PCR System (Applied 
Biosystems, Grand Island, NY) with TaqMan Universal PCR Master Mix (Applied 
Biosystems, Grand Island, NY) or Power SYBR Master Mix (Applied Biosystems, Grand 
Island, NY).  qPCR was performed using human Taqman probes (Applied Biosystems, 
Grand Island, NY): HES1: Hs00172878_m1, HES5: Hs01387463_g1, MUC2: 
Hs03005094_m1, K13: Hs00999762_m1, K8: Hs01670053_m1, K20: Hs00300643_m1, 
HATH1: Hs00245453_s1, KLF4: Hs00358836_m1 and β-ACTIN: NM_001101.2.  The 
following human SYBR green primers were used for: K5, K14, K18, K19, MUC3B, 
MUC5B, MUC17, DSC1, DSC3 and β-ACTIN, primers sequences in Methods Table 2. 
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Methods Table 2: SYBR green primers 
GENE 
(HUMAN) FORWARD PRIMER REVERSE PRIMER 
K5 TTCTTTGATGCGGAGCTGT CATGGAGAGGACCACTGAGG 
K14 GTCTGGCCGCGGATGAC GATGTCGGCTTCCACACTCA 
K18 AAAGGCCTACAAGCCCAGAT CACTGTGGTGCTCTCCTCAA 
K19 GATGAGCAGGTCCGAGGTTA TCTTCCAAGGCAGCTTTCAT 
MUC3B AGGTGGGCATGGAAGTGTCT CTGTAGGCCTGGGAAGTGTTG 
MUC5B GCTGCTGCTACTCCTGTGAGG AGGTGATGTTGACCTCGGTCTC 
MUC17 GGGCCAGCATAGCTTCGA GCTACAGGAATTGTGGGAGTTCA 
DSC1 TCTTCGAGTTCCTTCTCATCTTCAG GATTAGGCTGGCCGACTTGA 
DSC3 TTCTCAGGCGTGCCAAGAG GAAAGGGCCCAAGGAATTCT 
β-ACTIN CCTGGCACCCAGGACAAT GCCGATCCACACGGAGTACT 
 
Western Blotting 
Western Blot analysis was performed as described previously (Grugan, Vega et al. 
2013; Stairs, Nakagawa et al. 2008).  The following primary antibodies were used in 5% 
Milk in 1X PBS-T (0.1% Tween-20): MYC 1:250 (SantaCruz, Dallas, TX), CDX1 1:1000 
(Abcam, Cambridge, MA), β-ACTIN (Sigma, St. Louis, MO) 1:15000, KLF4 1:15000 
(Biosource/QCB graciously provided by Jonathan P. Katz, University of Pennsylvania), 
HES1 1:1000 (Abcam, Cambridge, MA).  The GFP (Cell Signaling, Beverly, MA) primary 
antibody was used at 1:1000 in 5% BSA in 1X PBS-T (0.1%Tween-20).  Secondary 
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antibodies (HRP-mouse, HRP-rabbit) were used at 1:5000 in 5% Milk in 1X PBS-T.  
Blots were developed using ECL Plus reagent (Invitrogen, Carlsbad, CA).  Signals were 
quantified by densitometry. 
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Chapter II: 
 
Figures and Figure Legends 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1:  Notch signaling is decreased in human Barrett’s esophagus.  
Microarray analysis from seven samples of Barrett’s esophagus (BE) and their adjacent 
normal squamous esophagus for status of Notch signaling pathway, GEO accession 
#GSE13083. (B) Representative image of normal esophagus and Barrett’s esophagus 
tissue from tissue microarray (TMA) stained for NOTCH1, ICN1 and HES1 
Magnification). (C) Average scoring for positive staining in the TMA and statistical 
analysis using Fisher’s exact t
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(A) 
(200X 
 Figure 2: Inhibition of Notch signaling 
cell morphology in 3D cultures. 
CDX1 in EPC2-hTERT, MYC
assay with Notch-responsive pGL3
MYC-CDX1-ICN1-dnMAML cells, graph represents mean ± SEM (n=3). Student t
was performed to determine significance, *p
Notch downstream targets HES1 and HES5 in MYC
cells. Graph represents mean ± SEM (n=3) and student t
determine significance, *p
cultures of MYC-CDX1 and MYC
(200X Magnification).  (E) Electron microscopy of MYC
3D organotypic cultures, scale bars=0.2µm. (F) Graph represents relative height of 
MYC-CDX1 and MYC-CDX1
test was performed to determine significance, *p
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in esophageal epithelial cells changes basal 
(A) Western blotting for GFP (dnMAML), MYC and 
-CDX1 and MYC-CDX1-dnMAML cells.  (B) Luciferase 
-8XCSL reporter vector in MYC-CDX1
≤0.05. (C) Quantitative PCR (qPCR) for 
-CDX1 and MYC-CDX1
-test was performed to 
≤0.05. (D) H&E staining of representative 3D organotypic 
-CDX1-dnMAML cells, arrow indicates elongated cells, 
-CDX1 and MYC-
-dnMAML basal layer cells mean ± SEM (n=4). Student t
≤0.0001. 
 
-ICN1 and 
-test 
-dnMAML 
CDX1-dnMAML 
-
 Figure 3: Inhibition of Notch signaling in 
squamous K13+ cells and increases columnar K19+ cells in 3D organotypic 
culture.   IHC staining of 
columnar keratin K19 (B) in MYC
(right panel) (200X and 400X Magnification). 
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esophageal epithelial cells decreases 
3D organotypic cultures for squamous keratin K13 (A) and 
-CDX1 (left panel) and MYC-CDX1-dnMAML cultures 
 
 
 Figure 4: Inhibition of Notch signaling in 
switch from the squamous lineage to a columnar lineage. 
keratins K5, K13 and K14; (B) columnar keratins K8, K18, K19 and K20; (C) mucin 
genes MUC2, MUC3B, MUC5B and MUC17; (D) and differentiation genes DSC1 and 
DSC3 in MYC-CDX1 and MYC
(n=6). Student t-test was performed to determine significance, *p
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esophageal epithelial cells p
qPCR of (A) squamous 
-CDX1-dnMAML cells. Graph represents mean ± SEM 
≤0.05, **p
 
romotes a 
≤0.001. 
 Figure 5: KLF4 knockdown reverses partially the morphological changes induced 
by Notch signaling inhibition i
CDX1 and MYC-CDX1-dnMAML cells. (B) Western blotting for KLF4 in EPC2
MYC-CDX1 and MYC-CDX1
shScramble and MYC-CDX1
MYC-CDX1-dnMAML-shScramble and MYC
staining of MYC-CDX1-dnMAML
organotypic cultures (400X Magnification). Graph represents mean ± SEM (n=6). 
Student t-test was performed to determine significance, *p
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n 3D cultures. (A)  qPCR of KLF4 expression in MYC
-dnMAML cells. (C) qPCR of KLF4 in MYC-
-dnMAML-shKLF4 cells. (D) Western blotting for KLF4 in 
-CDX1-dnMAML-shKLF4 cells. (E) H&E 
-shScramble and MYC-CDX1-dnMAML
≤0.01. 
 
-
-hTERT, 
CDX1-dnMAML-
-shKLF4 3D 
 Figure 6: HATH1 knockdown partially reverses changes induced by Notch 
signaling inhibition in esophageal epithelial cells. 
MYC-CDX1 and MYC-CDX1
dnMAML-shScramble and MYC
keratins K8, K18, K19 and K20; (D) mucin genes MUC2, MUC3B, MUC5B and MUC17;  
(E) squamous keratins K5, K13, K14; (F) and squamous differentiation markers DSC1 
and DSC3 in MYC-CDX1
cells. Graph represents mean ± SEM (n=6). Student t
significance, *p≤0.05. 
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(A) qPCR of HATH1 expression in 
-dnMAML cells. (B) qPCR of HATH1 in MYC
-CDX1-dnMAML-shHATH1 cells. qPCR of (C) columnar 
-dnMAML-shScramble and MYC-CDX1-dnMAML
-test was performed to determine 
 
-CDX1-
-shHATH1 
 Figure 7: KLF4 knockdown reverses lineage changes induced by Notch signaling 
inhibition in esophageal epithelial cells. 
and K20; (B) mucin genes MUC2, MUC3B, MUC5B and MUC17; (C) squamous keratins 
K5, K13 and K14; (D) and  squamous differentiation markers DSC1 and DSC3 in MYC
CDX1-dnMAML-shScramble and MYC
mean ± SEM (n=6). Student t
**p≤0.001. 
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qPCR of (A) columnar keratins K8, K18, K19 
-CDX1-dnMAML-shKLF4 cells. Graph represents 
-test was performed to determine significance, *p
 
-
≤0.01, 
 Figure 8: Model.  Inhibition of Notch signaling in conjunction with MYC and CDX1 
expression promotes increased expression of columnar keratins and mucin genes as 
well as decreased expression of squamous keratins and other markers of differentiation. 
Inhibition of Notch also triggers changes in cell morphology in the basal layer.
of Notch signaling promotes KLF4 expression and the initiation of a transdifferentiation 
program towards a BE-like metaplasia.
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Supplementary Figures 
 
 
 
 
 
 
 Supplemental Table 1: Tissue Microarray scoring for Notch signaling IHC positive 
staining in human Barrett’s esophagus. 
was scored for positive staining in a scale from 0
with Fisher’s exact t-test 
56 
 TMA staining for HES1, NOTCH1
-2.  Statistical analysis was performed 
comparing normal squamous to Barrett’s esophagus.
 
 and ICN1 
 
  
Supplemental Figure 1:
transdifferentiation.  qPCR 
(C) mucins MUC2, MUC3B
K14; (E) KLF4 and Hath1 in 
Graph represents mean ± SEM (n=6), student t
statistical significance, *p
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  Knockdown of HES1 in MYC-CDX1 cells does not cause 
of (A) HES1; (B) columnar keratins K8, K18, K19 and K20;  
, MUC5B and MUC17; (D) squamous keratins K5 ,K13 and 
MYC-CDX1-shScramble and MYC-CDX1-sh
-test was performed to determine 
≤0.01. 
 
 
 
 
HES1 cells. 
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Abstract 
BE is characterized by the presence of an intestinal columnar epithelium and 
mucin-producing goblet cells.  BE is the major risk factor for the development of 
esophageal adenocarcinoma (EAC).  Esophageal cancer is one of the deadliest cancers 
in the US, with a 5- year survival rate of 17.3% in 2013.  In the US, there has been an 
increase in the cases of EAC.  The rise of EAC can be associated with the increased 
prevalence of BE.  It is critical to develop in vivo models for BE and EAC.  Therefore, we 
sought to develop a genetic mouse model for BE by overexpressing MYC and CDX2, 
specifically in the esophageal squamous epithelium.  We first designed a mouse with 
conditional expression of MYC in the esophageal epithelium.  In order to achieve this we 
created a Tet-ON system using the Epstein-Barr virus L2 (EBV-L2) promoter 
(designated L2-rtTA), which is specifically active in the esophageal epithelium.  Our 
system allows us to activate MYC overexpression post-weaning by feeding the mice Dox 
(doxycycline) chow.  Secondly, we bred our L2-rTta; TetOp-Myc mice with Keratin14-
Cdx2 (K14-Cdx2) mice.  Herein, we demonstrate the activation of MYC and CDX2 
specifically in the mouse esophagus.  To date, we have observed no significant changes 
in the histology of the esophagus of the L2-rtTA; Tet-Op-Myc; K14-Cdx2 mice with or 
without 0.3% deoxycholic acid (DCA) treatment.  Current and future experiments 
involving aging the mice, as well as crossing with mice in which Notch signaling is 
inhibited.            
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Introduction  
BE is characterized by the presence of differentiated intestinal columnar cells 
and mucin-producing goblet cells.  Classically, BE studies focus on analysis of genetic 
alterations found in human BE biopsies.  Interestingly, BE is characterized by a mosaic 
pattern of genetic alterations, complicating the identification of initiating genetic changes 
that lead to BE.  In order to study the mechanisms leading to the development of BE, 
certain in vitro and in vivo models have been generated.  Current in vitro models for the 
study of BE include: 2D cell culture, 3D organotypic cultures and ex vivo transplantation 
models.  Cell culture models for BE include the use of the immortalized esophageal 
epithelial cell lines (EPC2) and immortalized BE cell lines (CP-A, CP-B, CP-C and CP-D) 
(Garman, Orlando et al. 2012).  Interestingly, the use of 3D organotypic cultures allows 
the evaluation of the interactions between epithelial cells and the stroma (Kalabis, Wong 
et al. 2012).  Recent studies using 3D organotypic cultures to grow the BE immortalized 
cell lines (CP-A, CP-B, CP-C and CP-D) show heretogeneity between all four cell lines 
when grown in 3D cultures (Kosoff, Gardiner et al. 2012).  An alternative system to 3D 
culture system is the use of an ex vivo system, namely a heterotypic rat trachea 
transplantation model (Croagh, Redvers et al. 2012).  Recent studies using this system 
have shown that Sox9 expression in mouse esophageal epithelial cells promotes K8 
expression and columnar differentiation (Clemons, Wang et al. 2012).  The use of these 
cell culture models all allow for the evaluation of gene regulation in a controlled 
environment, but the environment can differ greatly from that found in vivo. 
Limited in vivo models have been developed for the study of BE and EAC.  In 
one such model, rats undergo an esophagojejunostomy that results in massive bile 
reflux.  Post-surgery these rats develop BE and EAC (Gibson, Zaidi et al. 2013).  This 
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surgical model allows for the evaluation of potential therapeutics.  Treatment with a 
Smoothened inhibitor leads to a decreased incidence of BE and EAC in rats (Gibson, 
Zaidi et al. 2013).  However, this rat surgical model has limitations due to technical 
difficulty and high mortality rate post-surgery.  Moreover, the development of tumors in 
this model relies excessively upon bile reflux, which may not be physiologic.   
Recent work has focused on the development of genetic models in mice to study 
BE and EAC.  Studies of a p63 global knockout mice show the expansion of residual 
embryonic cells upon the loss of the esophageal squamous epithelium.  These residual 
embryonic cells replace the squamous epithelium with a columnar lined esophagus 
(Wang, Ouyang et al 2011).  One caveat of this model is that the p63 knockout mice are 
embryonic lethal and survive minimally in the post-natal period.  Another study with 
transgenic mice engineered to overexpress IL-1β and treated with bile in the drinking 
water revealed that the mice develop esophagitis, BE and EAC.  Furthermore, lineage 
labeling of the gastric cardia stem cells by Lgr5-GFP showed the presence of gastric 
cardia derived cells in the BE lesions (Quante, Bhagat et al. 2012).  Findings from the 
L2-IL1β mice model have shown the important role inflammation plays for the 
development of BE.  Given our previous in vitro studies that show MYC and CDX1 
overexpression in esophageal epithelial cells leads to transdifferentiation toward BE 
(Stairs, Nakagawa 2008).  We sought to develop a genetic mouse model for BE by 
overexpressing MYC and CDX2, specifically in the esophageal squamous epithelium, to 
test if transdifferentiation can lead to BE.    
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Results 
Vector design and generation of new transgenic mice: L2-rtTA; Tet-Op-CreERT2 
and Tet-Op-Myc 
In order to achieve the conditional expression of MYC, we designed a Tet-ON 
system, driven by the EBV-L2 promoter.  The EBV-L2 promoter has been shown to be 
active by our group in the mouse oral cavity (Nakagawa, Wang et al. 1997).  We first 
designed a vector (pRIL) with the EBV-L2 promoter driving expression of rtTA 
(tetracycline transactivator) (Figure 1A).  Furthermore, we inserted an HA-tagged 
luciferase, in order to optimize the detection of cells with EBV-L2 promoter activity 
(Figure 1A).  Next, we sought to add the ability to induce expression of the Cre 
recombinase specifically by the EBV-L2 promoter.  Therefore, we created a vector (pG-
CreERT2) with the Tet-Op promoter driving expression of CreERT2, a modified Cre 
recombinase fused to the estrogen receptor (ERT2) (Figure 1B), which allows for 
activation of the Cre by treatment with tamoxifen.  Next, we designed a vector (pGIT-
Myc) expressing the Tet-Op promoter driving expression of MYC; we also labeled the 
expression of this vector with FLAG-tagged TdTomato downstream of the Tet-Op 
promoter (Figure 1C).                 
We proceeded to prepare the vectors for DNA microinjection into mice.  
Therefore, we digested our DNA constructs with the Pac I restriction enzyme, which led 
to the linearization of the DNA construct.  This also allowed for the removal of the DNA 
vector backbone.  We confirmed proper quantification and purification of the linearized 
DNA (Supplemental Figure 1).  DNA microinjection was performed by the Transgenic 
and Chimeric Mouse Facility into C57BL/6 fertilized eggs.  The injections were done in 
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the following combinations: (A) pRIL+ pG-CreERT2 and (B) pGIT-Myc (Figure 2).  
Subsequent to the DNA microinjection, we received two founder (F1) mice for each 
mouse line: L2-rtTA; Tet-Op-CreERT2 and Tet-Op-Myc (Figure 2A-B).  We confirmed the 
genotyping for each of the mouse lines in the F2 generations (Supplemental Figure 2A-
B).  Thus, our L2-rtTa; Tet-Op-CreERT2 mice express the rtTA promoter in the squamous 
oral cavity, esophagus and forestomach.  Furthermore, treatment with doxycyline (dox) 
activates the binding of the rtTA transcription factor to the Tet-Op promoter and 
promotes the activation of CreERT2 or MYC (Figure 2A-B). 
L2-rtTA; Tet-Op-CreERT2 mice show specific expression of luciferase in 
esophagus and squamous forestomach 
Next, we proceeded to confirm the expression of luciferase in the L2-rtTA; Tet-
Op-CreERT2 mice.  We isolated tissue from the esophagi and squamous forestomachs of 
the mice.  We observed significant luciferase activity in the esophagus (Figure 3A) and 
squamous forestomach (Figure 3B) in both founders of the L2-rtTA; Tet-Op-CreERT2 
mice, compared to wild type control littermates.  Furthermore, we observed no luciferase 
activity in our negative control tissue (liver) (data not shown).  These results confirm the 
specific expression of our L2-rtTA; Tet-Op-CreERT2 double transgenic vectors restricted 
to the esophagus and squamous forestomach in both founder mouse lines.  
K14-rtTA; TetOp-Myc mice show activation of MYC expression in mouse 
esophagus 
We proceeded to verify the function of the Tet-Op promoter in the Tet-Op-Myc 
mice.  To activate the expression of the promoter, we bred our Tet-Op-Myc mice to the 
K14-rtTA mice (Nguyen, Rendl et al. 2006).  The K14 promoter is expressed in the skin, 
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salivary gland and mammary-gland epithelium.  In addition, it is expressed in epithelial 
cells of other tissues, including tongue, esophagus, forestomach and thymus (Wang, 
Zinkel et al. 1997).  In order to activate the Tet-ON system, the experimental K14-rtTA; 
Tet-Op-Myc mice and control mice were treated with 2g/L doxycycline in 5% sucrose for 
a period of 2 weeks.  Mice were sacrificed at the end of the treatment period.  We 
collected the esophagus and liver (negative control).  We performed 
immunohistochemistry (IHC) for Myc protein expression in the esophagi of the K14-rtTA; 
Tet-Op-Myc and wild type mouse tissue (Figure 4).  We observed significant positive 
staining for Myc protein in the K14-rtTA; Tet-Op-Myc esophagi compared to the wild type 
esophagi (Figure 4).  Our findings confirm that the Tet-Op-Myc transgenic mice can be 
activated by the K14 promoter expressing rtTA with the additional treatment of 
doxycycline.    
L2-rtTA; Tet-Op-Myc; K14-Cdx2 mice show no significant histological changes in 
the esophagus and squamous forestomach 6 or 12 months post-treatment with 
doxycycline 
We proceed to breed the L2-rtTA; Tet-Op-CreERT2 mice with the Tet-Op-Myc 
mice (Figure 5A).  From this breeding strategy we were able to generate the L2-rtTA; 
Tet-Op-Myc mice.   These mice are able to overexpress MYC specifically in the 
esophagus and forestomach when treated with doxycycline.  Next, we bred the L2-rtTA; 
Tet-Op-Myc mice with the K14-Cdx2 mice (Figure 5B).  The K14-Cdx2 mice have been 
described previously to overexpress Cdx2 in the mouse esophageal and squamous 
forestomach epithelia (Kong, Crissey et al. 2011).  From this breeding we were able to 
generate the L2-rtTA; Tet-Op-Myc; K14-Cdx2 experimental mice (Figure 5B). 
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Next, we treated the L2-rtTA; Tet-Op-Myc and L2-rtTA; Tet-Op-Myc; K14-Cdx2 
mice, and wild type control littermates, with doxycycline-diet chow starting at 1 month of 
age.  For our preliminary studies we sacrificed mice at 6 and 12 months post-treatment 
with doxycycline-diet.  Hematoxylin and eosin (H&E) staining of sections of the esophagi 
and squamous forestomachs, showed no significant histological changes at either 6 
(n=1) or 12 (n=3) months of age (data not shown).  Furthermore, we analyzed the 
esophagi for MYC and Cdx2 expression by IHC (Figure 6A-B).  We observed positive 
staining for MYC in the L2-rtTA; Tet-Op-Myc and L2-rtTA; Tet-Op-Myc; K14-Cdx2 mice 
and weak background staining in the wild type mice (Figure 6A).  Moreover, we 
observed positive staining for Cdx2 in the L2-rtTA; Tet-Op-Myc; K14-Cdx2 and K14-
Cdx2 mice (Figure 6B, Supplemental Figure 3A).  We confirmed Cdx2 overexpression 
by the K14-Cdx2 mice by western blotting of the esophagus, forestomach and tongue 
tissues (Supplemental Figure 3B).             
L2-rtTA; Tet-Op-Myc; K14-Cdx2 mice treatment with 0.3% deoxycholic acid (DCA) 
did not show significant alteration of the esophagus or squamous forestomach 
epithelium 
Previous studies by Quante et al. have shown that treatment of mice with 0.3% 
deoxycholic acid (DCA), starting at 3 months of age, accelerates the appearance of BE 
lesions in their L2-IL1β (Interleukin 1β) mice (Quante, Bhagat et al. 2012).  Therefore, 
we sought to investigate whether in L2-rtTA; Tet-Op-Myc; K14-Cdx2 mice the additional 
treatment with 0.3% DCA in the drinking water would promote changes towards BE.  We 
started treatment of our L2-rtTA; Tet-Op-Myc and L2-rtTA; Tet-Op-Myc; K14-Cdx2 mice 
and wild type control mice with doxycycline-diet at 1 month of age and then 0.3% DCA in 
the drinking water at 3 months of age.  We sacrificed mice at 12 months (n=2 for each 
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group) after the start of the doxycycline treatment and analyzed the esophagus and 
squamous forestomach by H&E staining.  We did not observe any significant histological 
changes (data not shown)     
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Discussion 
We have designed and generated a mouse model for the inducible expression of 
MYC and stable Cdx2 expression in the esophagus and squamous forestomach.  In 
order to achieve this we created a Tet-ON system using the EBV-L2 promoter.  Our 
system allows us to activate MYC overexpression post weaning by feeding the mice Dox 
chow (doxycycline).  Here, we show the activation of the Tet-Op-Myc promoter by in the 
K14-rtTA mice and our double transgenic L2-rtTA; Tet-Op-CreERT2 mice, upon treatment 
with doxycycline.      
Following the successful overexpression of MYC in the mouse esophagus we 
sought to activate the expression of Cdx2.  Therefore, we bred our L2-rTta; TetOp-Myc 
mice with the previously described K14-Cdx2 mice (Kong, Crissey et al. 2011).  We 
confirmed the expression of Cdx2 in the esophagus under the regulation of the K14 
promoter.  Previous studies of the K14-Cdx2 mice have shown that expression of Cdx2 
in the esophageal epithelium leads to a decrease in proliferation of basal cells and 
decreased cell to cell adhesion due in part by decreased expression of Desmocollin 3.  
Interestingly, we did not observe any changes the histology of the esophagi and 
forestomachs of the L2-rtTA; Tet-Op-Myc; K14-Cdx2 mice at either 6 or 12-months of 
age.  In preliminary studies, analysis for changes in expression of squamous keratin 13 
(K13) and columnar keratin 8 (K8) showed no changes (data not shown).  Treatment of 
mice with 0.3% DCA for 12-months caused no significant changes in the L2-rtTA; Tet-
Op-Myc; K14-Cdx2 mice in preliminary results.   
While, our preliminary studies show a lack of histological changes in the L2-rtTA; 
Tet-Op-Myc; K14-Cdx2 mice, we will plan to further analyze these for changes towards a 
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BE phenotype by aging the mice.  First, we will analyze the esophagi of L2-rtTA; Tet-Op-
Myc; K14-Cdx2 mice treated with 0.3% DCA for changes in gene expression of 
columnar (i.e. K8, K19, K20) and squamous keratins (i.e. K5, K13, K14) by IHC staining.  
Secondly, given previous results found in the K14-Cdx2 mice, we will analyze for 
changes in basal cell proliferation (i.e. Ki67) and cell to cell adhesion loss (i.e. 
Desmocollin-3 and electron microscopy).   
Lastly, our in vitro studies suggest that inhibition of Notch signaling (via dnMAML) 
in conjunction with MYC and CDX1 expression further promotes a BE-like metaplasia 
(Vega, Giroux et al. 2014).  Therefore, we propose to breed our L2-rtTA; Tet-Op-Myc; 
K14-Cdx2 mice with the Tet-Op-dnMAML/GFP mice (Fu, Chang et al. 2009) in order to 
inhibit Notch signaling in the mouse esophagus and forestomach, in conjunction with 
MYC and Cdx2 overexpression.  The Tet-Op-dnMAML/GFP mice express dominant 
negative Mastermind-like (dnMAML) fused to GFP driven by the Tet-Op promoter.    
Breeding of these mice expressing rtTA together with treatment with doxycycline leads 
to expression of dnMAML-GFP.  Currently, we are breeding of the L2-rtTA; Tet-Op-Myc; 
K14-Cdx2 mice with the Tet-Op-dnMAML/GFP mice.   
In our future studies we will treat the L2-rtTA; Tet-Op-Myc; K14-Cdx2; Tet-Op-
dnMAML/GFP mice with doxycyline to induce expression of MYC and dnMAML in the 
esophagus.  We expect inhibition of Notch signaling with MYC and Cdx2 may promote 
changes towards BE in vivo.  We plan to analyze the L2-rtTA; Tet-Op-Myc; K14-Cdx2; 
Tet-Op-dnMAML/GFP mice at 6 and 12 months of age post-treatment with doxycycline ± 
0.3% DCA.  We will analyze the esophagi for changes in cell morphology by H&E and 
electron microscopy.  Finally, we will also analyze these mice for changes in gene 
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expression of columnar (i.e. K8, K19, K20) and squamous keratins (i.e. K5, K13, K14) by 
qPCR and IHC staining.   
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Methods 
Vector subcloning  
Subcloning of CreERT2 and Myc into the pGIT vector was mediated by an initial 
subcloning to the pBluescript FS+ vector to add the Fse I and Sbf I sites for insertion to 
the pGIT vector.  First for CreERT2, we digested the pCAG-CreERT2 vector with Not I, 
followed by Klenow digest for blunting of Not I site, after which we cut with EcoR I.  We 
subcloned the CreERT2 into the pBluescript FS+ cut with EcoR I/EcoR V.  Screening for 
positive clones was done by double digest with Bgl II and EcoR I, with a 2kb band as the 
positive clone.  Before subcloning the CreERT2 to the pGIT vector we removed the 
tdTomato by Swa I digest followed by blunt ligation.  After removal of tdTomato in the 
pGIT vector, we cloned CreERT2 by Fse I and Sbf I sites.  For the pGIT-Myc subcloning, 
we first digested Myc from the Tet-O-Myc vector by EcoR I single digest, followed by 
ligation to the pBluescript FS+ vector to the EcoR I site.  Screening for correct direction 
of the Myc transcription start site was done by digest with EcoR V, with a 1.24kb band 
for the correct direction and Sbf I digest with 866bp band for the correct direction.  
Following digestion we sequenced positive colonies for confirmation before subcloning 
into the pGIT vector using Fse I and Sbf I sites.  All digests were performed using 
restriction enzymes from New England Biolabs (Ipswich, MA) following manufacturer’s 
protocols.  Sequencing of CreERT2 and Myc was performed after insertion to the 
pBluescript FS+ vector using the M13 Forward and M13 Reverse primers 
(Stratagene/Aligent, Santa Clara, CA). 
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Preparation of DNA for microinjection into oocytes 
We first digested 20µg of each pRIL, pGIT-Myc and pG-CreERT2 vector with Pac I (New 
England Biolabs, Ipswich, MA) at 37°C overnight, fo llowing the manufacturer’s 
instructions.  Next, we separated the linearized DNA by running the fragment on an 
agarose gel in 1X TAE, after which we excised the fragment from the gel.  We 
processed the gel fragments through Qiaex gel extraction kit (Qiagen, Germantown, 
MA), according to the manufacturer’s instructions.  We next ethanol precipitated the 
recovered DNA from this initial purification step.  Next, we passed the DNA through a 
Millipore Ultrafiltration Spin-Columns, 0.45µm cutoff (Millipore, Billerica, MA).  DNA 
recovered from this secondary purification step was resuspended in an injection buffer 
(10 mM Tris/0.1 mM EDTA, pH 7.5 prepared with distilled water).  Lastly, we estimated 
the DNA concentration by comparing the ethidium bromide staining of a sample run on 
an agarose gel next to a standard of known concentration, before submitting the 
samples for DNA microinjection. 
Mice 
All mouse studies and breeding were carried out under the approval of the Institutional 
Animal Care and Use Committee at the University Pennsylvania.  For short-term 
treatment with doxycycline, mice were placed on drinking water containing 2g/L 
doxycycline in 5% sucrose (protected from light) for a period of 2 weeks.  For long-term 
doxycycline treatment mice were administered a doxycycline by dox-diet chow 200mg/kg 
at one month of age (Bio-Serv, Flemigton, NJ).  For bile treatment mice were placed on 
drinking water containing bile acid (0.3% DCA, pH 7.0) at the age of three months.  
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Genotyping  
The following primers were designed for detection of trangene for the L2-rtTA; Tet-Op-
CreERT2 and Tet-Op-Myc mice. For genotyping the L2-rtTA; Tet-Op-CreERT2 mice we 
designed the iCre primers that detect the junction between Tet-Op promoter and 
CreERT2 and the rtTA primers that detect the junction between the EBV-L2 promoter and 
rtTA.  For the genotyping the Tet-Op-Myc we designed two sets of primers: TMyc which 
detects the junction between the Tet-Op promoter and Myc and TdTomato which detects 
the junction between the IRES and TdTomato.  All four primers sets have an annealing 
temperature of 60°C for 30 seconds.    
PRIMERS 
SET 
FORWARD REVERSE EXPECTED 
BAND SIZE 
iCre TTT CCC TGC CAC 
AGC TTG ATA GC 
TGT AAT TGA ACT 
GGG AGT GGA CAC C 
~ 250 bp 
rtTA GGG ACC ACA TAC 
ATC CCT GTC TCC 
TGG GCC AGC TTT 
CTG GTG G 
~ 250 bp 
TMyc GGT GGG AGG CCT 
ATA TAA GCA GAG C 
GGG CAG CAG CTC 
GAA TTT CTT CC 
~ 300 bp 
TdTomato GCC ACA ACG AGG 
ACT ACA CCA TCG 
GCT TCA CGT AAG 
CCT TGG ATC CG 
~ 300 bp 
 
Histology and Immunohistochemistry  
Hematoxylin and eosin (H&E) staining as well as immunohistochemistry (IHC) were 
performed as described previously (Stairs, Nakagawa et al. 2008).  The following 
antibodies were used for IHC: 1:500, Cdx2 (Abcam, Cambridge, MA) 1:500, MYC (Leica 
Biosystems, Richmond, VA).  Biotinylated secondary antibodies (Jackson 
Immunoresearch Laboratories Inc., West Grove, PA) and ABC avidin-biotin-DAB 
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detection kit (Vector Labs, Burlingame, CA) were used for detection and visualization 
according to supplier’s protocol. 
Statistical Analysis 
For relative luciferase expression changes in luciferase assay studies, statistical 
significance of comparisons between wild type and L2-rtTA; Tet-Op-CreERT2 founders 
F1 and F2 esophagus and squamous forestomach were determined by the student t-test 
with p<0.05 as statistically significant.  Error bars represent the mean ± SEM (Standard 
Error of the Mean) from at least triplicate experiments.  
Luciferase Assay  
Esophagi, forestomachs and livers (negative control) were harvested from wild type and 
L2-rtTA; Tet-Op-CreERT2 mice, and flash frozen to -80°C in dry ice.  Frozen  tissues were 
harvested for the luciferase assay following the “Preparation for Plant Tissue Lysate” 
protocol provided by the manufacturer’s protocol for lysate preparation.  The Luciferase 
Assay Kit (Promega, Madison, WI) was used for detection of luciferase activity following 
the manufacturer’s protocol.  
Western Blotting 
Western Blot analysis was performed as described previously (Grugan, Vega et al. 
2013; Stairs, Nakagawa et al. 2008).  The following primary antibodies were used in 5% 
Milk in 1X PBS-T (0.1% Tween-20): CDX2 1:1000 (Abcam, Cambridge, MA) and 
GAPDH 1:15,000 (Chemicon/Millipore, Billerica, MA). Secondary antibodies (HRP-
mouse, HRP-rabbit) were used at 1:5000 in 5% Milk in 1X PBS-T.  Blots were developed 
using ECL Plus reagent (Invitrogen, Carlsbad, CA).  
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 Figure 1: DNA vector design for generation of 
Myc transgenic mice.  The following vectors were designed to be used for the 
generation of novel transgenic mi
pGIT-Myc vector.  
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 and Tet-Op-
 Figure 2: DNA microinjection for the generation of 
Tet-Op-Myc mice.  Linearized DNA (A) RIL+G
microinjected into fertilized eggs by Transgenic and Chimera mouse facility.  Followin
this injection we generated two founder
Op-Myc.   
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 Figure 4: K14-rtTA; TetOp
esophagus.  Mice treated for 2 week with doxycyline in drinking water to activate the 
Tet-Op promoter expression of MYC.  IHC staining of 
wild type (left panel) and 
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esophagus for MYC expression in 
K14-rtTA; Tet-Op-Myc mice (right panel) (200X).
 
 
 Figure 5: Breeding strategy for development of a potential model of Barrett’s 
esophagus by overexpression of MYC and CDX2 in the mouse esophag
bred the Tet-Op-Myc mice to the 
Tet-Op-Myc mice. (B) Following the generation of the 
the K14-Cdx2 mice to generate the 
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Supplemental Figure 1: Linearized DNA quantification for microinjection into mice 
fertilized eggs.  Agarose gel picture of DNA after two step purification steps.
Quantification was verified by running DNA next to standard DNA amount of 100 ng.  
After correct quantification DNA was submitted to the Transgenic and Chimeric mouse 
facility.  
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 Supplemental Figure 2: Genotyping of 
mice. Representative agarose gel pictures for genotyping of (A) 
CreERT2 and (B) Tet-Op-
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L2-rtTA; Tet
Myc mice.  Positive mice +/tg and wild type mice +/+. 
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 Supplemental Figure 3: 
esophagus, forestomach and tongue show expression of CDX2.
CDX2 in esophagus of wild type
Western blotting for Cdx2 of 
forestomach.   
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Abstract 
There are two types of esophageal cancers: esophageal adenocarcinoma (EAC) 
and esophageal squamous cell carcinoma (ESCC).  ESCC is known to have a poor 
prognosis due to its late diagnosis and early metastasis.  Common genetic alterations 
found in ESCC include p53 mutations, p120catenin and p16 inactivation, as well as 
overexpression of oncogenes such as cyclin D1 and EGFR.  In our study using primary 
esophageal epithelial cells genetically transformed by the overexpression of EGFR and 
p53R175H (EPC-hTERT-EGFR-p53R175H), we find novel evidence of a link between 
p53R175H and the c-Met receptor tyrosine kinase to mediate tumor cell invasion.  We 
observed increased c-Met receptor activation (phosphorylation) specifically in the cells 
expressing the p53R175H mutation; this activation was further enhanced by EGFR 
overexpression.  Furthermore, c-Met phosphorylation was inhibited by using two small 
molecule compounds (CP31398 and 5-iminodaunorubicin) that have been demonstrated 
to activate wild-type p53 signaling.  Furthermore, both compounds inhibited invasion in 
the EPC-hTERT-EGFR-p53R175H cells, suggesting that the mechanism of increased 
invasivion upon EGFR and p53R175H expression may be the result of increased c-Met 
activation.  Taken together, mutant p53R175H and c-Met cooperate to foster tumor 
invasion in ESCC.  Therefore, our data suggest that targeting c-Met and p53R175H may 
prove useful for the treatment of ESCC.    
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Introduction 
 Worldwide, esophageal cancer is the eighth most common malignancy and the 
sixth most common cause of cancer-related death.  Esophageal cancer can be classified 
into two subtypes: esophageal adenocarcinoma (EAC) and esophageal squamous cell 
carcinoma (ESCC).  The incidence of EAC and ESCC varies by epidemiological features 
specifically ESCC is mainly seen in African-American and Asian populations.  
Furthermore, human squamous cell carcinomas are the most common type of epithelial 
cancers.  ESCC is an aggressive cancer with poor prognosis due to late diagnosis, local 
and distant metastases, and limited therapeutic options.  Globally, ESCC is the most 
common type of esophageal cancer diagnosed world-wide.  Risk factors for ESCC 
development include tobacco use, alcohol consumption, consumption of salt-cured, salt-
picked and moldy foods and consumption of hot beverages (Prabhu, Obi et al. 2014).   
The development of ESCC is a multistep, progressive process, and a number of 
genetic alterations in the tumor cells have been identified (Lehrbach, Nita et al. 2003; 
Okawa, Michaylira et al. 2007).  Some of the genetic alterations found in ESCC include 
activation of oncogenes such as EGFR and CyclinD1, inactivation of tumor suppressor 
genes p16, p120catenin and mutation p53 (Okano, Snyder et al. 2006).  Overexpression 
of EGFR has been reported in 60-70% of ESCC tumors (Hanawa, Suzuki et al. 2006).  
EGFR overexpression and p53 mutations are particularly common in premalignant 
lesions of ESCC (Volant, Nousbaum et al. 1995; Zhang 2013).     
P53 is a critical tumor suppressor gene that acts as a gatekeeper by maintaining 
cellular genomic stability and regulating cell growth.  In fact, loss of wild-type p53 or 
mutation in p53 is commonly found in many human cancers.  Most p53 mutations are 
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missense mutations, which are single base pair substitutions that occur in the DNA 
binding domain (DBD).  These mutations result in the loss of wild-type p53 function or a 
“dominant-negative” effect on wild-type p53 (Vousden and Prives 2009).  Among these 
mutations there are six “hot-spot” residues most commonly found in human cancers; 
these are R175H, G245S, R248W, R273H, R249S and R282W (Freed-Pastor and 
Prives 2012).  All these p53 mutations result in the stabilization and accumulation of the 
mutant p53 protein.  In ESCC the loss of function of p53 in ESCC is usually mediated by 
missense mutations at the DNA binding site.  Mutations R175H, R248W and R273H are 
commonly found in ESCC and are found to confer a selective growth advantage to 
increasingly malignant carcinomas (McCabe and Dlamini 2005).  These mutations can 
be separated into two categories: 1) mutations that directly block DNA binding by p53 
(R273H and R248W mutations – archetype) and 2) mutations that alter the global 
conformation of the p53 protein (R175H mutation – archetype).   
Mutations of p53 have been shown to influence tumorigenesis in multiple ways, 
including loss of the gatekeeper functions of wild type (WT) p53 by acting as a dominant 
negative directly on WT p53, and more recently appreciated, through WT p53-
independent gain of function (GOF) mechanisms.  In the latter context, the putative 
mechanisms involve abrogation of the effects of p63, an ortholog of p53, and direct DNA 
binding to a different repertoire of genes leading to activation by mutant p53.  Thereby, 
mutations of p53 could promote expression of genes not normally activated by the wild-
type p53.   
Clinically, tumors with p53 mutations carry a worse prognosis than those that are 
p53 null (Alsner, Sorensen et al. 2001; Poeta, Manola et al. 2007).  P53 null cells can be 
transformed by expression of mutant p53 (Olive, Tuveson et al. 2004).  Studies of mice 
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lacking one or both alleles of p53 show a predisposition towards development of 
osteosarcomas, lymphomas and lung cancers.  Conversely, mice models targeting 
specific p53 mutations have been generated to address the effect of p53 mutation in 
tumor development (Olive, Tuveson et al. 2004).  Interestingly, tumors in p53R172H/+ 
transgenic mice tend to be of more epithelial origin compared to p53-/- or p53+/- murine 
tumors and metastasize more than those from p53+/- mice (Olive, Tuveson et al. 2004; 
Lang, Iwakuma et al. 2004).  
The c-Met tyrosine kinase receptor activates a signaling response program 
termed “invasive growth” that is necessary both during normal embryonic development 
and adult tissue repair (Comoglio, Giordano et al. 2008; Comoglio and Trusolino 2002).  
C-Met receptor is normally expressed in epithelial tissue and can be activated by binding 
its ligand, namely hepatocyte growth factor (HGF) expressed by the mesenchymal cells.  
Specifically, upon activation there is trans-phosphorylation of Tyr 1234 and Tyr 1235 on 
the intracellular domain of c-Met, induction of docking molecules, and the activation of 
diverse signaling pathways, such as Ras, PI3K, STAT, β-catenin and Notch pathways 
(Trusolino, Bertorri et al. 2010).  
Perturbed activation of c-Met signaling has been shown to be important for 
neoplastic transformation in a wide variety of tumor types, including ESCC.  Activation of 
c-Met expression in cancer can trigger tumor growth, angiogenesis and promote 
metastasis.  These oncogenic activities are largely mediated through c-Met amplification 
or overexpression, although rare receptor mutations have been detected (Knudsen, 
Vande Woude et al. 2008; Joffre, Barrow et al. 2011).  Recent studies of genomic 
amplifications have identified that 1% of ESCC patients have c-Met gene amplification 
(Kato, Arao et al. 2013).  Studies of tissue microarrays of ESCC have shown an 
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increased expression of c-Met by 92%, compared to the normal esophageal epithelium 
(Hu, Lam et al. 2001).  Furthermore, clinical studies of ESCC patients have shown 
significant correlation between increased HGF serum levels and advanced tumor 
metastasis stage and decreased survival (Ren, Cao et al. 2005).      
 There is limited evidence linking p53 mutation and c-Met signaling in cancer.  
Sarcomas arising in Li-Fraumeni patients have increased c-Met protein levels (Rong, 
Donehower et al. 1995).  WT p53 was shown recently to regulate c-Met expression and 
influence cell migration and invasion in normal and transformed ovarian epithelium 
(Hwang, Matoso et al. 2011).  We have reported previously, using a model that 
recapitulates early genetic alternations in ESCC, that expression of mutant p53R175H and 
EGFR could transform immortalized human primary esophageal epithelial keratinocytes 
(EPC-hTERT), thereby dramatically increasing their migratory and invasive capabilities 
(Okawa, Michaylira et al. 2007).  In this study, we report a previously unidentified direct 
connection between p53R175H and increased c-Met receptor activity that is linked directly 
to tumor invasion. 
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Results 
Mutant p53R175H expression leads to c-Met activation in a HGF-ligand independent 
manner  
 Our previous studies using EPC2-hTERT cells retrovirally infected to express 
mutant p53R175H, show activation of c-Met pathway observed by increased c-Met 
phosphorylation.  Furthermore, c-Met phosphorylation is further upregulated upon EGFR 
overxpression (Grugan, Miller et al. 2010).  This specific pattern of activation was not 
shared with other selected receptor tyrosine kinases as IGF1Rβ and EGFR 
phosphorylation (data not shown).  Therefore, we sought to investigate mediators of this 
activation of c-Met phosphorylation in the EPC2-hTERT-EGFR-p53R175H cells.  In a 
certain context, EGF and HGF cooperate to promote cell proliferation, scatter and 
invasion in mouse mammary cells (Accornero, Miretti et al. 2010).  Recently, EGFR 
inhibition has led to the evaluation of targeting c-Met for EGFR inhibitor resistant tumors 
(Karamouzis, Konstantinopoulos et al. 2009; Jo, Stolz et al. 2000).  Thereby, we 
investigated whether the activation of c-Met was dependent on EGFR kinase activity.  
Interestingly, our inhibition of EGFR tyrosine kinase activity by pharmacological inhibitor 
(AG11478) did not affect c-Met activation (Figure 1A).  That being said, our results are 
not consistent with reports of the lack of cross-talk between EGFR and c-Met in mouse 
adult liver oval cells (Martinez-Palacian, del Castillo et al. 2012).   
 The c-Met tyrosine kinase receptor is classically activated by binding of its ligand 
HGF.  Therefore, we next investigated whether the c-Met activation observed in the 
EPC2-hTERT-p53R175H±EGFR was dependent on HGF.  In our experimental conditions, 
a c-Met inhibitor (PHA665752) decreased c-Met phosphorylation in the EPC2-hTERT-
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EGFR-p53R175H cells (Figure 1B).  But interestingly, c-Met phosphorylation was not 
affected by an HGF blocking antibody (previously optimized for blocking efficiency 
(Grugan, Miller et al. 2010)) in EPC2-hTERT-p53R175H±EGFR cells (Figure 1B-C).  
Thereby, our data suggests c-Met activation is not mediated by HGF ligand binding 
under these experimental conditions.  Further support of this conclusion emerges from 
the finding that HGF was undetectable in cell culture media (keratinocyte serum free 
medium, KSFM) or in conditioned media collected from EPC2-hTERT-EGFR-p53R175H 
cells (data not shown).    
We observed that c-Met phosphorylation was reduced when EPC2-hTERT-
EGFR-p53R175H cells were cultured in keratinocyte basal medium (KBM) or in KSFM 
without the added bovine pituitary extract (BPE) (Figure 1D), but was constitutively 
phosphorylated in KSFM with BPE ± additional EGF (normal culture conditions).  
Moreover, c-Met phosphorylation was not affected by eliminating the supplement of 
EGF.  These data suggest that there is a factor(s) in BPE that influence c-Met 
phosphorylation.  In order to determine if the p53R175H mediated c-Met phosphorylation 
was the result of the potential expression and autocrine secretion of an unidentified 
ligand capable of activating c-Met, cells with low/absent c-Met phosphorylation (EPC2-
hTERT-EGFR and EPC2-hTERT, respectively) were treated with conditioned media 
collected from EPC2-hTERT-EGFR-p53R175H cells (Figure 1E).  Our treatment with the 
condition media showed no increase in c-Met phosphorylation in either EPC2-hTERT-
EGFR or EPC2-hTERT cells, compared to the baseline c-Met phosphorylation in KSFM.  
Thereby these data lead us to conclude that c-Met activation upon p53R175H expression is 
ligand-independent, either HGF or some other ligand.   
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Phospho-Met expression is specific to the p53R175H mutation 
 Different mutations of p53 have been described to be found in ESCC.  Therefore, 
we sought to investigate whether other mutations of p53 could activate c-Met 
phosphorylation.  We analyzed a survey of primary esophageal keratinocytes expressing 
additional p53 mutations (R273H, V143A, or R248W) described previously (Okawa, 
Michaylira et al. 2007; Michaylira, Wong et al. 2010).  Our analysis for c-Met 
phosphorylation in EPC2-hTERT-p53(mutant)±EGFR with the following p53 mutations: 
R175H, R273H, V143A and R248W showed that the activation of the c-Met receptor 
upon p53 mutation was exclusive to R175H (Figure 2A). 
 Furthermore, we analyzed mouse esophageal keratinocytes (MEK) cells isolated 
from p53 null and WT mice with overexpression of the human p53R175H mutant 
(previously described) (Andl, Mizushima et al. 2003), for activation of c-Met pathway. 
Interestingly, we did not have similar patterns of c-Met activation (Figure 2B).  Overall, 
these cells showed no increased c-Met activation upon overexpression of the p53R175H 
mutation.  These differences between the human and mouse cell data might point to 
species differences due to the origin of the esophageal keratinocytes or the potential 
combinatorial effects of EGFR and p53R175H. 
Restoration of WT p53 function reverses p53R175H mutant activation of phospho-
Met and cell invasion 
 In order to determine if the increased c-Met phosphorylation was linked directly to 
p53 mutation, we used three pharmacologic activators of WT p53 signaling in order to 
restore normal p53 signaling.  First we used 5-iminodaunorubicin (5-ID) which has been 
identified for its cytotoxicity independent of the cellular p53 status and does so by 
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activating p53 family member p73 and downstream p21 (Wang, Kim et al. 2006).  Our 
treatment of ECP2-hTERT-EGFR-p53R175H with 5-ID shows decreased expression of c-
Met phosphorylation at 1.0µM and complete loss at 5.0µM (Figure 3A).  Secondly we 
used CP-31398 and PRIMA-1 which have been shown to bind to mutant p53 and alter 
its conformation so as to restore proper DNA binding (Lambert, Gorzov et al. 2009; 
Wischhusen, Naumann et al. 2003).  Treatment with CP-31398 compound resulted in a 
loss of c-Met phosphorylation in EPC-hTERT-EGFR-p53R175H cells with a concomitant 
upregulation of p21 (Figure 3B).  Moreover, PRIMA-1 treatment did not show an effect 
on phospho-Met or activation of p21 at 1µM or 10µM concentrations; treatments at 
higher doses proved to be toxic to the cells (Figure 3B).   
 We next sought to investigate whether the loss of c-Met phosphorylation in the 
EPC2-hTERT-EGFR-p53R175H by treatment with 5-ID and CP-31398 could affect cell 
proliferation and invasion.  Our analysis showed a decrease in cell proliferation with both 
5-ID and CP-31398 (Figure 3C).  Furthermore, both these compounds lead to a 
significant decrease in cell invasion in a boyden-chamber invasion assay (Figure 3D).  
Lastly, we used our three-dimensional (3D) organotypic culture system by which we can 
recreate the stratification of the esophageal epithelium in order to address the effects of 
these compounds on invasion.  Interestingly, we observed that the EPC2-hTERT-EGFR-
p53R175H (DMSO) show invasion into the matrix.  This invasion is loss significantly with 
the treatment with both 5-ID and CP-31398 (Figure 3E).  These experiments give 
credence to the premise that the increased tumor cell invasion apparent with p53R175H 
mutation is mediated in part by c-Met phosphorylation.   
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Discussion  
Human squamous cell carcinomas are the most common type of epithelial 
cancers.  One subtype, esophageal squamous cell carcinoma (ESCC), is an aggressive 
cancer with poor prognosis due in large by late diagnosis and limited therapeutic 
options.  Specifically, ESCC is typically inoperable and fatal when detected due to early 
metastasis of tumor cells.  Therefore, we have studied the genetic influences on 
esophageal tumor cell invasion, one of the initial critical steps of tumor dissemination 
and metastasis.  In our previous studies we have modeled ESCC, using immortalized 
human esophageal epithelial cells overexpressing EGFR and p53R175H (EPC2-hTERT-
EGFR-p53R175H), which when grown in 3D organotypic cultures result in invasion into the 
underlying extracellular matrix (Okawa, Michaylira et al. 2007).  Thereby, through this 
model system we can investigate the early invasion events characteristic of ESCC.  
Here, we report a novel connection between mutant p53R175H expression and 
activation of the c-Met receptor tyrosine kinase in a HGF ligand independent manner 
and potentially independent of other ligands.  One of the potential mechanisms to 
explain the link between p53R175H mutation and increased c-Met signaling in transformed 
esophageal keratinocytes could be due to direct transcriptional effect of the p53R175H on 
c-Met.  It has been shown that mutant p53 can activate a distinct gene transcription 
profile than that of wild type p53, which can vary depending on the particular p53 
mutation (Freed-Pastor, Prives et al. 2012).  Thereby, mutant p53 may have a direct 
transcriptional effect upon c-Met by virtue of its GOF properties (Lu, Liu et al. 2013).   
Interestingly, our data showed no significant changes in the c-Met RNA (data not shown) 
or protein expression in our cells overexpressing mutant p53R175H.   
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Another potential mechanism for c-Met tyrosine activation by p53R175H could be 
due to regulation of receptor trafficking.  Mutant p53 has been demonstrated to result in 
enhanced integrin and epidermal growth factor receptor (EGFR) trafficking, which 
depends upon Rab-coupling protein (RCP) and results in constitutive activation of 
EGFR/integrin signaling (Muller, Caswell et al. 2009).  To that end, mutant p53 may 
enhance c-Met signaling to promote cell scattering and invasion through both TAp63-
dependent and -independent mechanisms (Muller, Caswell et al. 2009; Muller, Trinidad 
et al. 2013), however, this is dependent upon HGF ligand binding the c-Met receptor, a 
scenario not present in our results, suggesting that our specific interrelationship between 
mutant p53 and c-Met is mediated through another mechanism.  
Recently, the miR34 family of microRNA was identified as a p53 transcriptional 
product and c-Met was confirmed to be a target of the miR34 family (Migliore, Petrelli et 
al. 2008; He, He et al. 2007; Siemens, Neumann et al. 2013).  We sought to investigate 
whether the any of the mir34 family member expression could correlate with the 
phosphorylation of c-Met we observed in our system.  Interestingly, we did find that 
mir34a is decreased in the p53R175H cells (data not shown).  However, we do not find that 
overexpression or knockdown of mir34a had an effect on either c-Met expression levels 
or phosphorylation of c-Met levels (data not shown).  Thereby, our data suggest the 
activation of c-Met signaling in our system is independent of p53R175H regulation of 
mir34a (Figure 4).   
Our findings suggest a HGF-independent activation of c-Met signaling by mutant 
p53R175H (Figure 4).  ESCC is a difficult cancer to treat.  Currently, neo-adjuvant or 
adjuvant therapy involves chemotherapy and radiation.  Biologics have gained some 
attention, although EGFR inhibition is not standard.  Since p53R175H is present in a 
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subset of ESCC (Soussi, Asselain et al. 2006) we propose that it would be intriguing to 
consider c-Met inhibition therapy in this context of a future pre-clinical study. 
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Methods 
Cell Culture 
Primary human esophageal keratinocytes, designated EPC2-hTERT, and their 
derivatives are described previously (Harada, Nakagawa et al. 2003).  The following 
mediums where used keratinocyte basal medium (KBM) from Lonza (Allendale, NJ) or 
using keratinocyte serum free medium (KSFM) (Invitrogen, Carlsbad, CA) without BPE 
(bovine pituitary extract) and EGFR supplements.  Stable transduction of primary 
esophageal cells with retroviral vectors was described previously (Michaylira, Wong et 
al. 2010; Harada, Nakagawa et al. 2003; Takaoka, Harada et al. 2004).  Briefly, pFB-neo 
retroviral vectors (Stratagene/Aligent, Santa Clara, CA) containing the entire coding 
sequence for the human EGFR (pFB-neo-WT-hEGFR), pBabe-puro-p53R175H  or pBabe-
puro-p53R273H or pBabe-puro-p53R248W or pBabe-puro-p53V143A were transfected into 
Phoenix-Ampho packaging cells (gift of Dr. Garry Nolan, Stanford University, Palo Alto, 
CA) using LipofectAMINE 2000 reagent (Invitrogen, Carlsbad, CA), according to the 
manufacturer’s instructions.  Culture supernatants from individual Phoenix-Ampho cells 
were used to infect EPC2–hTERT cells.  Cells were passaged 48 hrs after infection and 
selected with G418 (Invitrogen, Carlsbad,CA) (300 µg/mL), puromycin (EMD-Millipore, 
Billerica, MA) (0.5 µg/mL), for a period of 7 days, resulting in generation of control EPC2-
hTERT-EGFR-p53R175H, EPC2-hTERT-EGFR-p53R273H, EPC2-hTERT-EGFR-p53R248W, 
EPC2-hTERT-EGFR-p53V143A, EPC2-hTERT-neo-p53R273H and EPC2-hTERT-neo-
p53R248W cells. Independent infections and selections were performed to generate two 
additional cell lines of each genotype.  Mouse esophageal keratinocytes (MEK) isolated 
from p53 null mice (MEK3N p53K puro, MEK2N p53K) and wild type p53 mice (MEK3N, 
MEK3N puro) previously decribed 38, were transfected with human p53R175H, in both the 
99 
 
p53 null (MEK2 p53K p53R175H) and wt p53 (MEK3N p53R175H).  The following reagents 
were used in cell culture studies: AG1478 (Sigma, St. Louis, MO) EGFR tyrosine kinase 
inhibitor (1uM) for 120min; PHA665752 phospho-Met inhibitor (Tocris Bioscience, 
Minneapolis, MN); 5-iminodaunorubicin (5-ID) (gift of Dr. Wafik El-Deiry, Hershey, PA) 
range from 0.1-10uM; CP-31398 (50ng/mL-5ug/, mL) (Tocris Biosciences, Minneapolis, 
MN) and PRIMA1 (1uM-10uM) (Cayman Chemical, Ann Arbor, MI). 
Conditioned Media Treatment 
Condition media of EPC2-hTERT-EGFR-p53R175H cells grown in 2D cultures in KSFM 
medium, was collected after 48 hrs, collected medium was spun down for 5min at 
1000rpm to remove any cellular debris.  EPC2-hTERT-neo-puro or EPC2-hTERT-
EGFR-puro cells (0.5x106 per plate) where plated 24 hrs before treatment.  Condition 
medium was added after 24 hrs of growth, cells where harvested 24 hrs after for protein 
lysis previously described (Grugan, Miller et al. 2010).  
Western Blot Analysis 
Cells were harvested in lysis buffer [50 mM Tris·HCl (pH 8), 150 mM NaCl, 1% Nonidet 
P-40, 1% Triton X-100, 2 mM sodium orthovanadate, 10 mM sodium fluoride, 5 mM 
sodium pyrophosphate, protease inhibitor tablet (Roche, Indianapolis, IN).  Thirty 
micrograms of protein were run on a 4–12% SDS/PAGE Bis-Tris gel (Invitrogen, 
Carlsbad, CA) and transferred to a poly (vinylidene difluoride) membrane (Immobilon-P; 
Millipore, Billerica, MA).  Membranes were blocked in 5% nonfat milk (Bio-Rad Life 
Science, Hercules, CA) in PBS-T [1× PBS without Ca+2 and Mg+2 (Invitrogen, 
Carlsbad, CA) and 0.1% Tween 20] for 1 hr at room temperature.  Membranes were 
then probed with primary antibody diluted in 5% milk in PBS-T overnight at 4 °C, washed 
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with PBS-T, and incubated with anti-mouse or anti-rabbit secondary antibodies (1:5000 
in PBS-T) for 1 hr at room temperature and washed in PBS-T.  The signal was visualized 
using an enhanced chemiluminescence solution (ECL Plus; GE Healthcare Life 
Sciences, Piscataway, NJ) and exposed to Blue Lite Autorad film (ISC-BioExpress, 
Kaysville, UT). 
Antibodies 
Antibodies were obtained from the following sources: EGFR(Ab-12) (1:1000) 
NeoMarkers/Thermo Fisher Scientific (Waltham, MA), phospho-EGFR (Tyr1068) (1:500) 
and phospho-Met (Tyr1234/1235) (1:500) Cell Signaling Technology (Beverly, MA), Met 
antibody (C-28) (1:1000) Santa Cruz Biotechnology (Dallas, TX), p53 (Ab-6) (1:1000) 
Calbiochem (Billerica, MA), GAPDH (1:15000) Chemicon/Millipore (Billerica, MA) and 
p21 (WAF1 Ab-1) (1:1000) Calbiochem (Billerica, MA).  Anti-mouse and anti-rabbit 
horseradish peroxidase (HRP)-conjugated antibodies were from GE Healthcare Life 
Sciences (Piscataway, NJ).  Mouse IgG1 control antibody was from R&D Systems 
(Minneapolis, MN).  2B8 mouse anti-human HGF IgG1 generated from hybridoma 
(AVEO Pharmaceuticals, Cambridge, MA) and mouse IgG1 control antibody from R&D 
Systems (Minneapolis, MN), where used in HGF blocking antibody experiment, as 
previously described (Grugan, Miller et al. 2010). 
Cell proliferation WST-1 assay 
5000 cells where plated in 100ul of KSFM in a 96-well plate for 72 hrs before reading 
with WST-1 reagent (Roche, Indianapolis, IN).  After 48 hrs of growth, we added 5-ID 
and CP-31398 reagents at described concentrations.  After 24 hrs 10ul of WST-1 
reagent and incubated at 37°C for 2 hrs.  Following  incubation plate was read using 
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ELISA plate reader to measure absorbency.  All experiments were performed in triplicate 
on three independent days. 
Boyden Chamber Invasion assay  
For invasion assays, insert plates (8-µm pore size, 24-well insert) coated with growth 
factor reduced Matrigel matrix were used (BD Biosciences, San Jose, CA).  Inserts were 
placed in a 24-well plate containing DMEM + 10% serum to stimulate cell invasion. 
1×105 cells in serum-free medium were placed in each insert (plus the 5-ID or CP-
31398). Twenty hours later, the cells remaining inside the insert were removed with a 
cotton swab and the invading cells on the insert bottom were labeled with 4 µg/mL 
Calcein AM dye (Invitrogen, Carlsbad, CA) in Hanks’s Balanced salt solution (HBSS) 
(Invitrogen, Carlsbad, CA) for 30 min at 37°C. The labeled cells were then read on a 
Biotek FLX800 multidetection microplate reader (BioTek, Winooski, VT) at 485 nm 
excitation and 528 nm detection. All experiments were performed in triplicate on three 
independent days. 
Organotypic culture 
H&E staining of organotypic 3D cultures show 5-ID and CP-31398 treatment can reduce 
invasion.  The employment of EPC cells and their derivative cell lines in organotypic 
culture was done as described previously (Kalabis, Wong et al. 2012).  The cultures 
were harvested and fixed for 1 hr or overnight in 10% buffered formalin phosphate 
(Fisher, Waltham, MA) before being paraffin-embedded and sectioned (Leica RM2155 
microtome; Leica Microsystems, Buffalo Grove, IL) for hematoxylin and eosin (H&E) 
staining. 
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Statistical Analysis 
Boyden-chamber invasion assay were analyzed for statistical significance comparing 
cells treated with vehicle versus CP-31398 or 5-ID using the Student t-test, with p≤0.05 
as statistically significant.  Error bars represent the mean ± SEM (Standard Error of the 
Mean) from at least triplicate experiments.  
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Chapter IV: 
Figures and Figure Legends 
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Figure 1: p53R175H expression leads to c-Met activation in an HGF-independent 
manner. (A) Inhibition with AG11478 EGFR tyrosine kinase inhibitor (1uM) for 120 mins.  
(B-C) Inhibition with anti-HGF antibody or the PHA665752 phospho-Met inhibitor.  (D) 
Activation of phospho-Met in EPC2-hTERT-EGFR-p53R175H can be attenuated by using 
keratinocyte basal medium (KBM) or using keratinocyte serum free medium (KSFM) 
without BPE (bovine pituitary extract) and EGFR supplements.  (E) Treatment of cells 
with condition media from EPC2-hTERT-EGFR-p53R175H cells does not activate 
phospho-Met in EPC2-hTERT-neo-puro or EPC2-hTERT-EGFR-puro.  
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Figure 2: Phospho-Met expression is specific to the p53R175H mutation. (A) Panel of 
four different p53 mutations R175H, R273H, R248W and V143A were analyzed by 
Western Blotting for phospho-Met expression. Only the cells expressing the p53R175H 
mutant have increased phospho-Met expression.  (B) Mouse esophageal keratinocytes 
(MEK) isolated from p53 null mice (MEK3N p53K puro, MEK2N p53K) and wild type p53 
mice (MEK3N, MEK3N puro) were transfected with human p53R175H, in both the p53 null 
(MEK2 p53K p53R175H) and wt p53 (MEK3N p53R175H).  The p53R175H did not have the 
same effect on activation of phospho-Met as in human keratinocytes.  
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Figure 3: Restoration of WT p53 function reverses p53R175H mutant activation of 
phospho-Met. (A-B) EPC2-hTERT-EGFR-p53R175H cells treated for 24 hrs with 5-
iminodaunorubicin (5-ID) in a range from 0.1-10uM (A), CP-31398 (50ng/mL-5ug/mL) 
(B) show decrease in  phospho-Met levels by western blotting; treatment with PRIMA1 
(1uM-10uM) (B) had no effect in the levels of phopho-Met.  (C)  Treatment with 5-ID 
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(range 0.1uM-10uM) and CP-31398 (range (0.01ug/mL-10ug/mL) inhibited cells growth 
of EPC2-hTERT-EGFR-p53R175H in WST-1 assay (C)  Error bars represent ± SEM, and 
Student’s t-test was used to determine significance (*, P ≤ 0.05).  (D) Treatment of 
EPC2-hTERT-EGFR-p53R175H with 5-ID (1uM and 5uM) and CP-31398 (2ug/mL and 
5ug/mL) caused a decrease in boyden-chamber invasion assay. (C-D) Error bars 
represent ± SEM, and Student’s t-test was used to determine significance (*, P ≤ 0.05).  
(E) H&E staining of organotypic 3D cultures show 5-ID (3uM) and CP-31398 (5ug/mL) 
treatment can reduce invasion, Magnification 100X.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4: Model.  Through an in vitro model of ESCC using human esophageal 
epithelial cells transformed by overexpression of EGFR and p53
evidence of a functional link between p53
mediate tumor invasion.  Our data shows activation of c
phosphorylation) by p53R175H
activation of c-Met signaling is not mediated by p53
Overall, our model support c
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Role of inhibition of Notch signaling in initiation of Barrett’s 
esophagus 
 Throughout our study in Chapter II, we focus on Barrett’s esophagus (BE), an 
incomplete intestinal metaplasia of the esophagus, a known precursor of esophageal 
adenocarcinoma (EAC).  The biological mechanisms leading to the development of BE 
remain to be clarified.  Several hypotheses have been proposed as to the cell of origin 
for BE (DeVault, McMahon et al. 2013).  Currently, these hypotheses remain the subject 
of investigation.  One such model is the transdifferentiation of the esophageal squamous 
epithelium, which served as the focus of our investigation.  Through our study in Chapter 
II we sought to provide evidence in support of the premise of transdifferentiation of 
esophageal epithelial cells as the potential cell of origin for the initiation of BE.   We did 
not seek to prove or disprove other premises. We believe also that it is possible that 
more than one cell type might serve as the origin of BE, and this may be very context 
dependent.     
In Chapter II, we demonstrate that Notch signaling is downregulated in human 
BE, suggesting that development of intestinal metaplasia in the esophagus could require 
inhibition of Notch signaling.  Furthermore, Notch inhibition via dominant-negative 
Mastermind (dnMAML), in conjunction with MYC and CDX1 expression, promotes 
transdifferentiation in our immortalized esophageal epithelial cells.  We observed the 
appearance of elongated columnar-like cells in the basal layer of 3D organotypic 
cultures of the MYC-CDX1 cells with Notch inhibition (dnMAML).  Moreover, the MYC-
CDX1-dnMAML cells show a switch in genes that denote the BE lineage, characterized 
by a robust diminution of squamous keratins and differentiation markers in favor of a 
strong induction of columnar keratins and mucins.  Taken together, these data suggest 
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during the development of BE the activation of MYC and CDX1, and the negative 
regulation of the Notch signaling pathway, can cause changes in the esophageal 
epithelial cells associated with transdifferentiation towards BE.   
Since our 3D organotypic culture system limits us to the study of esophageal 
basal cells, we could potentially test other hypotheses independently of what has been 
published already.  Work from Dr. Tim Wang’s lab has shown the successful culture 
mouse gastric cardia cells (personal communication).  These cells could be modified 
with MYC, CDX1 and dnMAML to explore if a BE phenotype is present, at least in 3D 
organotypic culture.  Esophageal submucosal glands are absent in the mouse and only 
present in humans. This is an impediment but one could evaluate potential stem cell 
genes for expression in this compartment.  
Yet, it is important to note that despite the alterations observed in the MYC-
CDX1-dnMAML cells, they were still able to form a stratified epithelium in our 3D 
organotypic cultures.  Since our 3D organotypic culture system is designed to promote 
the stratification of esophageal epithelial cells, it would be useful to further investigate 
alternative 3D organoid culture systems.  Given, that these MYC-CDX1-dnMAML cells 
show the initiation of changes towards BE, we would expect the use of 3D system which 
promotes the growth of an intestinal-like epithelium, we might observe further evidence 
of transdifferentiation towards BE.   In addition, our current findings suggest the need for 
additional genetic alterations may be required for the complete development of BE in our 
model system.  Therefore, it would be interesting to address whether p16 LOH in 
addition to MYC, CDX1 and Notch inhibition will further promote transdifferentiation to 
BE.  Genetic studies of human BE have shown that p16 LOH as an early event in the 
development of BE (Maley, Galipeau et al. 2004).   
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We sought next to investigate the mechanism through which the inhibition of 
Notch signaling in MYC-CDX1 cells promotes potential for transdifferentiation.  Previous 
studies have shown Notch signaling can be a negative regulator of both KLF4 and 
HATH1 transcription factors (Zheng, Pritchard et al. 2009; Kazanjian, Noah et al. 2010).  
Interestingly, we observed the upregulation of both KLF4 and HATH1 upon Notch 
signaling inhibition in our system.  Furthermore, we showed knockdown of either KLF4 
or HATH1 in the MYC-CDX1-dnMAML cells partially reversed the changes observed 
upon Notch inhibition.  Overall, our findings suggest that KLF4 and HATH1 might be 
mediators of the changes in gene expression and cell morphology observed in our MYC-
CDX1-dnMAML cells.  It would be interesting to investigate further whether knockdown 
of both KLF4 and HATH1 together would lead to a complete reversal of the changes 
observed upon Notch signaling inhibition.  Moreover, it would be interesting to 
investigate whether KLF4 and HATH1 can directly bind the promoters of BE lineage 
specific genes to promote their activation by ChIP.  In addition, we could investigate for 
novel targets for KLF4 and HATH1 in the context of transdifferentiation towards BE by 
ChIP-seq.  Furthermore, we could investigate further whether the decreased expression 
of Notch signaling expression correlates with upregulation of KLF4 and HATH1 in human 
BE.  If so, KLF4 and HATH1 activation may serve as potential early biomarkers for the 
detection of BE. 
Our findings in Chapter II suggest collaboration between MYC, CDX1 and Notch 
signaling inhibition in promoting transdifferentiation towards BE and this is mediated in 
part by KLF4 and HATH1.  How do these transcriptional factors interact, if at all?  Our 
preliminary studies with both CDX1 and CDX2 overexpression, in conjunction with MYC, 
in esophageal epithelial cells; demonstrate increased K8 and K20 expression by qPCR 
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(data not shown).  Furthermore, inhibition of Notch signaling in these CDX1-CDX2-MYC 
cells showed a further increase of both K8 and K20 (data not shown).  It is conceivable 
that CDX1 and CDX2 cooperate through trans-activation of the other’s gene promoter 
(Grainger, Hryniuk et al. 2013). 
A global and unbiased approach would be to determine if there is overlapping 
binding of gene promoters involving CDX1, CDX2, MYC, KLF4 and HATH1. This would 
involve ChIP-Seq, recognizing the complexity of this approach. Additionally, we could 
analyze whether MYC, CDX1/CDX2, KLF4 and/or HATH1 bind to the promoters of BE 
lineage genes (columnar keratins, mucins) by ChIP.  If there is overlap, we could 
determine if there is protein-protein interaction between specific transcriptional factors, 
performing ChIP-on-ChIP. Since inhibition of Notch signaling is critical, there may be 
some direct or indirect effect upon one or more of these transcriptional factors. 
Recent studies have shown that activation of Notch signaling occurs in EAC.  
Interestingly, our tissue microarray (TMA) show increased NOTCH1, ICN1 and HES1 
expression in low-grade dysplasia and high-grade dysplasia (data not shown).  
Furthermore, our preliminary studies for the gene expression status in BE cell lines for 
Notch signaling show decreased expression of HES1 and HES5 in the non-dysplastic 
CP-A cells, and show increased HES1 and HES5 in the high-grade dysplasia CP-D cells 
(data not shown).  These preliminary findings suggest that re-activation of Notch 
signaling occurs during the progression from BE to EAC.  Therefore, it would be 
interesting to investigate in future experiments the role of Notch signaling in the 
progression of BE to EAC.                              
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Design and development of a genetic mouse model of Barrett’s 
esophagus 
The modeling of diseases through the use of in vivo mouse models can provide 
significant information regarding not only the mechanism leading to a disease, but also 
provide a physiological system in which to test potential therapies.  Therefore, through 
our study in Chapter III, we sought to design a potential genetic mouse model for BE.  
First, we designed a mouse model that would allow us to overexpress MYC in the 
esophagus.  In Chapter III, we show the successful generation of an inducible Tet-ON 
mouse system that leads to the overexpression of MYC in the esophagus upon 
treatment with doxycycline.  Second, we bred the L2-rtTA; Tet-Op-Myc mice with the 
K14-Cdx2 mice (Kong, Crissey et al. 2011) in order to achieve overexpression of MYC 
and Cdx2 in the esophagus.  Our preliminary findings show the L2-rtTA; Tet-Op-Myc; 
K14-Cdx2 show no significant histological changes at 6 or 12 months of age with or 
without treatment with 0.3% DCA.  Therefore, we plan to analyze further our L2-rtTA; 
Tet-Op-Myc; K14-Cdx2 mice treated with 0.3% DCA for gene expression changes in 
columnar keratins (i.e. K8, K19, K20) and squamous keratins (i.e. K5, K13, K14) by 
qPCR and IHC.   
 The lack of histological changes in the esophagi and forestomach of the L2-rtTA; 
Tet-Op-Myc; K14-Cdx2 could be due to the requirement of Notch signaling inhibition to 
promote changes in cell morphology.  Thus, we propose to breed the L2-rtTA; Tet-Op-
Myc; K14-Cdx2 mice with the Tet-Op-dnMAML/GFP mice.  Through this breeding 
strategy we expect to acquire mice with overexpression of MYC and Cdx2, and Notch 
signaling inhibition specifically in the esophagus and forestomach.  We propose to 
analyze the esophagi and forestomach of the L2-rtTA; Tet-Op-Myc; K14-Cdx2; Tet-Op-
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dnMAML/GFP mice 9, 12 and 15 months post-treatment with doxycycline chow ± 0.3% 
DCA.  We expect Notch signaling inhibition in conjunction with MYC and Cdx2 
overexpression may lead to changes in the cell morphology of the basal cells, similar to 
those observed in 3D organotypic culture.  We predict our mice will show increased 
expression of columnar keratins, and mucins genes.  Moreover, we plan to make use of 
the tdTomato (Tet-Op-Myc mice) and GFP (Tet-Op-dnMAML/GFP mice) to isolate and 
sort the esophageal epithelial cells for further analysis through spheroid and organoid 
assays.  
Our findings in Chapter II suggest KLF4 as a potential mediator of Notch 
signaling inhibition promoting the transdifferentiation to BE.  Therefore, an alternative to 
breeding with the Tet-Op-dnMAML mice, we could breed our L2-rtTA; Tet-Op-Myc; K14-
Cdx2 mice with the L2-KLF4 mice (Tetreault, Wang et al. 2010).  The L2-KLF4 mice 
have been show to have increased basal esophageal cell proliferation, increased 
expression of inflammatory cytokines.   Furthermore, L2-KLF4 mice show dysplasia by 6 
month of age, and develop ESCC by 2 years.  Therefore, we could investigate the role of 
KLF4 overexpression in the context of MYC and Cdx2 and whether it may promote 
transdifferentiation towards BE. Our study of the L2-rtTA; Tet-Op-Myc; K14-Cdx2; Tet-
Op-dnMAML/GFP mice will allow us to pursue the hypothesis of transdifferentiation of 
esophageal basal cells to BE.  We expect our mice will acquire changes in gene 
expression towards BE lineage markers and decreased expression of squamous lineage 
markers.   
Our mouse model may have potential utility in the prevention, detection and 
therapy of human BE, all areas that are filled with challenges.  First, it is believed that 
certain drugs, such as aspirin, proton pump inhibitors or statins, might be 
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chemopreventive agents in human BE (Falk, Buttar et al. 2012; Tsibouris, Vlachou et al. 
2014).  These could be tested directly in our mouse model, recognizing such studies 
would entail a great deal of time.  Second, if we lineage-labeled our mice with YFP, then 
we could determine if such cells circulate in blood, and interrogate these cells for 
potential biomarkers that may be applicable to patients with various stages of BE.  We 
could conduct genomic studies, either genomic or whole-exome sequencing, to 
determine what the profile of mutations in genes is, and compare to human BE.  This 
has not been done to date in human BE.  Such a comparison may also contribute to the 
development and application of biomarkers in human BE.   
We cannot assume that our mice will develop EAC. Aging of mice will help to 
evaluate that possibility.  Furthermore, we could breed our mice to the L2-IL1β mice.  
The L2-IL1β mice develop esophagitis, BE and EAC (Quante, Bhagat et al. 2012).  
Therefore, we expect expression of IL-1β in conjunction with MYC and Cdx2 
overexpression and Notch inhibition may promote to the acceleration of BE to EAC. 
Such compound mice may prove to be attractive models for the investigation of novel 
therapeutics.  Currently, early stage EAC is subjected to neoadjuvant chemoradiation 
therapy followed by surgery.  Otherwise, therapy tends to be restricted to palliative 
measures for advanced stages of EAC.  To that end, targeted therapeutics, linked to 
genomic alterations in BE and/or EAC, as well as the tumor microenvironment, might be 
feasible in our mouse model  
Activation of c-Met receptor tyrosine kinase by a common p53 
mutation (R175H) enhances tumor invasion in ESCC 
Esophageal cancer is one of the deadliest cancers in the US.  Esophageal 
cancer is subdivided into two major subtypes: esophageal adenocarcinoma (EAC) and 
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esophageal squamous cell carcinoma (ESCC).  In Chapter IV, we investigated the role 
of a common p53 mutation R175H in enhancing ESCC invasion, mediated by activation 
of the c-Met receptor.  In our study we used immortalized esophageal epithelial cells 
overexpressing EGFR and p53R175H (EPC2-hTERT-EGFR-53R175H) and grew in 3D 
organotypic cultures.  In Chapter IV, we show EPC2-hTERT-EGFR-p53R175H cells harbor 
activation of the c-Met, with increased c-Met phosphorylation.   
Interestingly, our findings show the activation of c-Met is not mediated by 
increased expression of its ligand HGF.  Furthermore, our data show activation of c-Met 
is specific to the p53R175H mutation.  Therefore, our data suggest a novel connection 
between mutant p53R175H expression and activation of the c-Met receptor.  Throughout 
our study in Chapter IV, we sought to investigate potential mechanisms to explain the 
link between p53R175H and c-Met activation.  Through our studies using pharmacological 
reagents which lead to the restoration of wild-type p53, we demonstrate the activation of 
c-Met is dependent upon the presence of the mutant p53 function.  Interestingly, our 
data showed no significant changes in RNA or protein levels of c-Met in the EPC2-
hTERT-EGFR-p53R175H cells.  Another potential mechanism p53R175H mediated activation 
of c-Met is through p53 regulation of the miR34 family.  Our findings demonstrate 
decreased expression of mir34a in the EPC2-hTERT-EGFR-p53R175H cells.  Yet, 
knockdown or overexpression of mir34a had no effect on activation of c-Met.  Therefore, 
our data suggest c-Met activation by p53R175H is mediated in a mir34a independent 
mechanism. 
 Our findings in Chapter IV suggest the need to further investigate the mechanism 
through which p53R175H mediates activation of the c-Met receptor.  Interestingly, recent 
studies have shown PAK1 can mediate activation of c-Met receptor in breast cancer 
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(Shrestha, Schafer et al. 2012).  Therefore, it would be interesting to investigate whether 
p53R175H can activate PAK1 to mediate activation of c-Met.  Interestingly, our preliminary 
studies show increased active PAK1 in the EPC2-hTERT-EGFR-p53R175H cells, as 
observed by phosphorylation of PAK1.  Moreover, studies of p53 mediated apoptosis in 
rat kidney cells show PAK1 can act downstream of wild-type p53 (Thomas, Giesler et al. 
2000).  Thus, we propose further investigation of PAK1 signaling in the context of our 
EPC2-hTERT-EGFR-p53R175H cells.           
Overall our findings in Chapter IV demonstrate an HGF independent activation of 
c-Met by mutant p53R175H.  Interestingly, in our model of ESCC, the restoration of wild-
type p53 function led to decreased invasion in 3D organotypic cultures.  Currently, 
treatment of ESCC is limited due to late diagnosis where invasion and metastasis are 
present.  Therefore, our findings provide potential evidence for the development of novel 
therapeutic treatments targeted to restoration of p53 wild-type function or c-Met 
inhibition.                
Concluding Remarks 
 Overall, our collective data in Chapter II highlight the potential mechanism of 
transdifferentiation as the possible initiation of BE in 3D organotypic culture.  Our data 
suggest that overexpression of MYC and CDX1 in conjunction with inhibition of Notch 
signaling may foster transdifferentiation and this may be mediated through KLF4 and 
HATH1.  Furthermore, our findings provide the basis to investigate these pathways in an 
in vivo context.  We expect that the future studies of Chapter III may provide further 
novel insights to support transdifferentiation of the esophageal basal cells as a potential 
cell of origin for BE. 
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Lastly, our studies in Chapter IV we demonstrate a novel link between p53R175H 
and c-Met in mediating cell invasion in ESCC.  Thus, our data support the need to 
explore new targeted therapeutic treatments for ESCC with a focus on p53 and c-Met.         
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